БИОРЕЗОРБИРУЕМЫЙ ПЕРЕВЯЗОЧНЫЙ МАТЕРИАЛ ДЛЯ РАН

Изобретение относится к медицине и представляет собой нетканый материал для доставки GDF-5-родственного белка, содержащий волокна волокнистого сырьевого материала, включающие биорезорбируемые и/или биосовместимые полимеры, причем эти волокна содержат GDF-5-родственный белок, включающий цистин-узел-домен с идентичностью аминокислот по меньшей мере 60% относительно 102 аа-цистин-узел-домена GDF-5 человека, соответствующих аминокислотам 400-501 SEQ ID NO: 2. Указанный GDF-5-родственный белок распределен в волокнах. Изобретение относится также к повязке для ран, прокладке для ран и импланту, которые содержат указанный нетканый материал. 4 н. и 13 з.п. ф-лы, 9 ил., 4 пр.

ГЕМОСТАТИЧЕСКАЯ ГУБКА

Группа изобретений относится к медицине. Описана гемостатическая пористая композитная губка, содержащая матрицу из биоматериала и один гидрофильный полимерный компонент, содержащий реакционно-способные группы, при этом матрица и полимерный компонент соединяются друг с другом так, что реакционная способность полимерного компонента сохраняется, при этом «соединенный» означает, что указанный полимерный компонент наносится на поверхность указанной матрицы из биоматериала, или указанная матрица пропитывается указанным полимерным материалом, или и то и другое. Губка демонстрирует низкое набухание после применения на ране. 7 н. и 8 з.п. ф-лы, 9 ил., 27 пр., 1 табл.

КОМПОЗИЦИОННАЯ КОЛЛАГЕНОВАЯ ГУБКА И СПОСОБ ЕЕ ИЗГОТОВЛЕНИЯ

Изобретение относится к медицине. Композиционная коллагеновая губка предназначена для остановки кровотечения, а также для стимулирования роста и пролиферации клеток. Губка содержит коллаген, факторы роста клеток и защитный агент в количестве 10%-50% масс., где защитный агент содержит аминокислоты, сахариды и альбумин в массовом отношении 1-11:1,25-17,5:1-7,5. Способ изготовления губки включает этап вирусной инактивации, который включает две стадии: первая стадия представляет собой вирусную инактивацию органическим растворителем/детергентом; вторая стадия представляет собой 30-120-минутную обработку раствора губки на водяной бане при 90-100°C, и ее проводят в присутствии защитного агента. Технический результат заключается в том, что губка имеет водопоглощающую способность более чем 52 раза на основании массы губки и имеет модуль упругости более 70,0 Н/см. Губку можно подвергать вирусной инактивации в течение продолжительного времени при высокой температуре, в то время как биоактивность коллагена ...

ЖЕЛАТИН-ТРАНСГЛУТАМИНАЗНЫЕ КРОВООСТАНАВЛИВАЮЩИЕ ПОВЯЗКИ И ИЗОЛИРУЮЩИЕ СРЕДСТВА

Группа изобретений относится к медицине, а именно к травматологии и хирургии, и может быть использована для остановки кровотечения. Для этого используют композицию, а также адгезивный материал, содержащие желатин и трансглутаминазу, где их соотношение является достаточным для уменьшения кровотечения в ране и где указанный желатин не подвергается необратимому гелеобразованию и образует раствор с трансглутаминазой при температуре ниже естественной гель-золь перехода стандартного животного желатина, полученного из животного источника или представляющего собой рекомбинантный желатин или их комбинацию. Использование данных изобретений позволяет сократить время остановки кровотечения в ране. 2 н. и 20 з.п. ф-лы, 19 ил., 11 табл., 15 пр.

КОМПЛЕКСЫ ТИПА САХАРИДНАЯ ЦЕПОЧКА-ПОЛИПЕПТИД

Изобретение относится к комплексам типа сахаридная цепочка-полипептид, которые могут образовывать прозрачный и однородный гидрогель в широком диапазоне рН. Комплексы сахаридная цепочка-полипептид характеризуются тем, что данный полипептид представляет собой полипептид, содержащий аминокислотную последовательность, состоящую из 8-34 аминокислотных остатков, в которой чередуются полярные и неполярные аминокислотные остатки, и с данным полипептидом связана одна или несколько сахаридных цепочек, и общее число сахаридных остатков, присутствующих в одной или нескольких сахаридных цепочках, связанных с указанным полипептидом, составляет 5 или больше. 6 н. и 9 з.п. ф-лы, 7 ил., 6 табл., 10 пр.

ХИРУРГИЧЕСКИЕ БАРЬЕРЫ С ИНГИБИРУЮЩИМИ ОБРАЗОВАНИЕ СПАЕК СВОЙСТВАМИ

Изобретение относится к медицине. Описан хирургический барьер, который включает в себя обращенное к ране полимерное покрытие, содержащее энтеросолюбильный полимер; и по меньшей мере один гибкий носитель, где упомянутый по меньшей мере один гибкий носитель имеет по меньшей мере одну внешнюю поверхность, причем упомянутое полимерное покрытие наносится на упомянутый по меньшей мере один гибкий носитель так, чтобы существенно покрыть упомянутую по меньшей мере одну внешнюю поверхность носителя. Также описаны способ блокирования образования спаек у пациента, перенесшего хирургическое вмешательство, и способ заживления прободения желудка и двенадцатиперстной кишки. Способ позволяет уменьшить вероятность или предотвратить образование спаек, связанных с хирургическим вмешательством. 4 н. и 23 з.п. ф-лы, 4 табл., 7 пр.

Биополимерные пленки с углеродными наноматериалами

Настоящее изобретение относится к области медицины, а именно к биополимерной пленке для использования в хирургии и комбустиологии, получаемой на основе желатина и гидрофильного биополимера ПЭГ-1500 в пропорции 1:1, структурированной углеродными наноматериалами: ОУНТ-ПВП, или ОУНТ-СМС, или НП-44 в количестве 0,04% масс. Настоящее изобретение обеспечивает углеродные наноматериалы пленки, которые обладают способностью к удержанию влаги, биодеградируют, не подавляют метаболические процессы в клетках и удерживают воду в сравнении с контролем на 50-80%. 4 пр., 1 табл., 2 ил.

ГЕМОСТАТИЧЕСКОЕ БИОЛОГИЧЕСКИ АБСОРБИРУЕМОЕ УСТРОЙСТВО С ПОЛИЭТИЛЕНГЛИКОЛЕМ В КАЧЕСТВЕ СВЯЗУЮЩЕГО ВЕЩЕСТВА

Гемостатическая прокладка, содержащая биологически абсорбируемый каркасный материал; порошок лиофилизированного тромбина, порошок лиофилизированного фибриногена и порошок плавкого связующего вещества, причем все порошки размещены на биологически абсорбируемом каркасном материале. Плавкое связующее вещество, такое как PEG, связывает порошок лиофилизированного тромбина и порошок лиофилизированного фибриногена с биологически абсорбируемым каркасным материалом для улучшения характеристик осыпаемости, смачиваемости и эффективности при применении, таком как гемостатическое лечение или уплотнение тканей в месте расположения раны. 11 з.п. ф-лы, 3 ил., 3 табл.

ХИРУРГИЧЕСКИЕ БАРЬЕРЫ С ИНГИБИРУЮЩИМИ ОБРАЗОВАНИЕ СПАЕК СВОЙСТВАМИ

... 1. Хирургический барьер, включающий: ! а) обращенное к ране полимерное покрытие, содержащее энтеросолюбильный полимер; и ! б) по меньшей мере один гибкий носитель, где упомянутый по меньшей мере один гибкий носитель имеет по меньшей мере одну внешнюю поверхность, ! причем упомянутое полимерное покрытие наносится на упомянутый по меньшей мере один гибкий носитель так, чтобы существенно покрыть упомянутую по меньшей мере одну внешнюю поверхность носителя. ! 2. Хирургический барьер по п.1, где упомянутый энтеросолюбильный полимер выбирается из группы, состоящей из фталата гидроксипропилметилцеллюлозы; ацетатсукцината гидроксипропилметилцеллюлозы; энтеросолюбильных ацетатных производных; ацетата диметилцеллюлозы; энтеросолюбильных акрилатных производных; а также их производных, солей, сополимеров и их сочетаний. ! 3. Хирургический барьер по п.2, где упомянутое энтеросолюбильное ацетатное производное выбирается из группы, состоящей из поливинилацетатфталата, ацетатбутирата целлюлозы, ацетаттримеллитата ...

СПОСОБ ИЗГОТОВЛЕНИЯ ПОВЯЗКИ

... 1. Способ изготовления повязки, имеющей в своем составе, по меньшей мере, один белок, предусматривающий следующие стадии: ! (a) нанесения упомянутого, по меньшей мере, одного белка на упомянутую повязку; и ! (b) воздействие на упомянутую повязку, имеющую в своем составе, по меньшей мере, один белок, давлением, варьирующим от приблизительно 2500 до приблизительно 39500 пси, в течение времени от приблизительно 2 до приблизительно 6 секунд. ! 2. Способ по п.1, в котором повязка содержит вязаный, тканый или нетканый материал, желатиновую губку или коллагеновую губку. ! 3. Способ по п.2, в котором материал содержит волокна, содержащие полимеры алифатических полиэфиров или сополимеры одного или более мономеров, выбранных из группы, состоящей из молочной кислоты, лактида (включая L-, D-, мезо- и D, L смеси), гликолевой кислоты, гликолида, ε-капролактона, p-диоксанона и триметилена карбоната. ! 4. Способ по п.3, в котором материал содержит сополимер гликолида и лактида. ! 5. Способ по п.1, в котором ...

АППРЕТ, НЕ СОДЕРЖАЩИЙ СИНТЕТИЧЕСКИХ ПОВЕРХНОСТНО-АКТИВНЫХ ВЕЩЕСТВ, ЛИСТ С АППРЕТОМ, НЕ СОДЕРЖАЩИМ СИНТЕТИЧЕСКИХ ПОВЕРХНОСТНО-АКТИВНЫХ ВЕЩЕСТВ, ИЗДЕЛИЯ, ИМЕЮЩИЕ ЛИСТ С АППРЕТОМ, НЕ СОДЕРЖАЩИМ СИНТЕТИЧЕСКИХ ПОВЕРХНОСТНО-АКТИВНЫХ ВЕЩЕСТВ, И СООТВЕТСТВУЮЩИЕ СПОСОБЫ

Fibrindichtungsmittelzusammensetzungen und Verfahren zu deren Verwendung

HYDROGEL AUF BASIS VON ALBUMIN

Biodegradable fibrous material with very high swelling capacity and stability in swollen state

Biodegradable fibrous materials, which give fibre-reinforced gels on absorption of liquids, are coated with biodegradable polyelectrolyte solutions.

KÜNSTLICHE KÖRPERFLÜSSIGKEIT

TRÄGER MIT FESTEM FIBRINOGEN UND THROMBIN

Neurosurgical Sponge apparatus with dissolvable layer

Haemostatic wound dressing

Delivery of a botanical extract to a treated substrate for transfer to skin

The present invention relates in a combination for surface treatment of a substrate. e.g. a nonwoven web, used in personal care product applications. The surface treatment combination not only provides adequate fluid handling properties, but also provides a topical delivery system effective in depositing a thin, tenacious and substantially continuous coating of a botanical extract on skin by an aqueous emulsion mediated dissolution of the agent from a substrate with subsequent transfer and deposition onto the skin. Coatings of the botanical extract on the skin resist removal, thereby preventing damage to the natural skin barrier and providing a protective barrier against chemically- and biochemically-induced skin damage.

ENZYMATICALLY DISPERSIBLE NONWOVEN WEBS AND PADS

... 1451619 Laminates MINNESOTA MINING & MFG CO 6 Dec 1973 56546/73 Heading B5N [Also in Divisions A5 and D1-D2] Sanitary products of laminated construction include a ply which is readily dispersible in an aqueous medium containing an enzyme, said ply consisting of a non-woven web of fibres bonded together by a water-insoluble, enzymedisintegratable, solid binder which consists of a polymer of at least one ethylenically unsaturated monomer covalently bonded with a naturally occurring, enzyme-degradable, water soluble polymeric material, the binder being present in an amount from 0À3-100% by wt. of the fibres, sufficient to provide the fabric with a wet strength of at least 0À5 kg./cm.2 in an aqueous medium in the absence of an enzyme, and to increase the resistance of the fabric to dispersion in plain water whilst enabling dispersion of the fabric in a period of 5-30 minutes in an aqueous medium containing an enzyme capable of disintegrating the binder. The fibres may be rayon, cotton ...

A personal care product comprising a botanical extract

Wound dressings for the controlled release of therapeutic agents

Wound healing compositions

A human platelet cell proliferation factor (HPPF) has been isolated. This platelet factor is characterized as an acid stable, thermostable peptide having an apparent molecular weight in the range of 8,000 to 12,500 and an isoelectric point in the range of from 3.5 to 5.5. In combination with a co- factor selected from cell growth factors, cell attachment factors and plasminogen activators, and particularly epidermal growth factor (EGF), HPPF promotes the healing of wounds.

Lysozyme dimer and compositions containing the same

Biodegradable film of protection and absorbing plug using this film of protection.

BY SURGERY EFFECTIVE, ANTISEPTIC BIOLOGICAL FEDERATION AND PROCEDURE FOR ITS PRODUCTION

NEW AND CAREFUL PROCEDURE FOR THE TRANSFORMATION OF THE CYSTINS OF KERATINHALTIGEN MATERIALS IN LANTHIONIN

PROCEDURE FOR INTERLACING FILMS, FOILS AND BULK MATERIAL

HYGIENEODER CARE ARTICLE, EXHIBITING A PORTION OF HYDRAULICACTIVE POLYMERS, AND A PREPARATION EXHIBITING BACTERIOPHAGES OR AT LEAST ONE COMPONENT OF THE SAME

WUNDVERBAND WITH BALANCED PERMEABILITY.

PHARMACEUTICAL COMPOSITION.

PROCEDURE FOR THE PRODUCTION OF A KOLLAGEN OF SPONGE; EXTRACTION DEVICE OF A PART OF A KOLLAGEN SPONGE AND AN EXTENDING KOLLAGEN SPONGE

ENZYME-DEPENDENT THERAPEUTIC WUNDVERBÄNDE

STERILE COMPLEX OF A THERAPEUTIC PEPTIDS TO A POLYSACCHARID

ANTI-ENZYME ANTIBODY CONTAINING COMPOSITIONS FOR THE TREATMENT OF THE SKIN

MACROSCOPICALLY ORIENTATION CELL ADHESION PROTEIN TO WUNDBEHANDLUNG

Procedure for the production of sanitary products according to actually well-known methods from fiber courses

HUMAN ANTIBIOTIC PROTEIN

CARRIER WITH FIRM FIBRINOGEN AND THROMBIN

WUNDVERBAND AND CATHETER MOUNTING PLATE FROM A PU BIO POLYMER KOMPOSITMATERIAL

Water absorbent keratin and gel formed therefrom

Composition and method for treating burns

Hemostatic products

A hemostatic product that includes a fibrinogen mixture, a thrombin mixture and a biologically tolerable liquid. The fibrinogen mixture includes fibrinogen and at least one fibrinogen stabilizer. The thrombin mixture includes thrombin and at least one thrombin stabilizer. The biologically tolerable liquid is mixed with the fibrinogen mixture and the thrombin mixture to form the hemostatic product.

Composite dressings, manufacturing methods and applications thereof

The present disclosure provides a composite dressing comprising a combination of porous matrix and fabric substrate wherein at least one of said porous matrix and fabric substrate is composed biomaterial(s) and wherein the fabric substrate is at least partially embedded in the porous matrix. Further, the disclosure provides a method for preparation of said composite dressing, wherein said method enables production of the composite dressing having cohesive bonding between porous matrix and fabric support without use of any adhesive, stitching or chemical crosslinking agent between the two layers. The composite dressing exhibits high peel strength in both dry and wet conditions and has applications such as hemostatic dressings for deep cavity wounds, puncture wounds, post-partum hemorrhage and internal hemostatic agents.

ANTISEPTIC BIOLOGICAL DRESSING

Activated leukocyte conditioned supernatant and uses for wound healing

Disclosed are therapeutic, activated leukocyte conditioned supernatants, methods of making them, and methods of using the conditioned supernatants to repair or promote healing of wounds.

Bioresorbable wound dressing

The present invention is directed to novel non-woven fabrics containing growth and differentiation factor proteins. Said fabrics are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues. Furthermore, the invention provides wound dressings, pads or implants comprising the novel non-woven fabrics.

Antimicrobial and immunostimulatory system comprising an oxidoreductase enzyme

Hemostatic sponge

The present invention provides a hemostatic porous sponge comprising a matrix of a fibrous biomaterial and particles of a fluid absorbing, particulate material adhered to said matrix material, a method of producing these sponges and their use for wound healing.

FIBRIN/COLLAGEN MEMBRANE MATERIAL FOR BIOMEDICAL USE

COMPOSITION FOR THE PREPARATION OF HISTOLOGICAL, AUTOPSICAL, CYTOLOGICAL SAMPLES

Biopolymeric membrane for wound protection and repair

The present invention relates to a conformable and semi-permeable biopolymeric membrane suitable for tissue repair and protection. This membrane contains a first layer made from randomly oriented, reconstituted biopolymer fibers and, on top of the first layer, a coating layer made from biopolymer fibers.

Dry composition comprising an extrusion enhancer

Disclosed is a dry composition comprising one or more polyols, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures. The paste reconstitutes spontaneously upon addition of the liquid;hence no mechanical mixing is required for said paste to form. The composition may further comprise an extrusion enhancer, such as albumin. Also disclosed are methods of preparing said dry composition, a paste obtained from said dry composition and uses of said dry composition or paste for medical and surgical purposes.

Bilayered devices for enhanced healing

Disclosed herein is a multilayered wound dressing comprising a first layer; the first layer including channels that facilitate neovascularization of a wound; and a second layer in contact with the first layer, the second layer having the same or different chemical composition as the first layer; where the second layer comprises at least one surface that has a texture and the direction of the texture is operative to facilitate cell orientation and growth. A method includes forming a first layer of a polymeric material; forming a second layer of the same polymeric material as the first layer on the first layer; and forming a textured surface of the second layer of the same polymeric material as the first layer, the textured surface being operative to facilitate directional cell growth when used in a wound dressing, where the first layer and the second layer are formed using an additive manufacturing process.

Self-supporting sheet-like material of cross-linked fibrin for preventing post operative adhesions

Surgical sutures containing spider silk

NATURAL PROTEIN POLYMER HYDROGELS

Human antibiotic proteins

WOUND DRESSINGS COMPRISING A PROTEIN POLYMER AND A POLYFUNCTIONAL SPACER

There is described a method of forming a wound dressing. The method comprises forming a protein polymer by reacting a protein with a polyfunctional spacer, or an activated derivative thereof. The polyfunctional spacer is preferably a polycarboxylic acid, especially a dicarboxylic acid, and protein polymers prepared using such spacers are suitable for a wide range of therapeutic applications, including use as wound dressings, for the delivery of therapeutically active agents to the body and as bioadhesives and sealants.

STERILE COMPLEX OF THERAPEUTIC PEPTIDE BOND TO A POLYSACCHARIDE

The invention provides sterile compositions comprising a complex of a therapeutic peptide and a polysaccharide selected from the group consisting of cellulose derivatives, chitin, chitosans, galactomannans, and mixtures thereof, wherein the complex has been sterilised with ionising radiation. The presence of the polysaccharides surprisingly stabilizes therapeutic peptides against decomposition under ionising conditions, especially under gamma- irradiation. Processes for the preparation of the sterile compositions and processes for the preparation of sterile therapeutic peptides are also claimed.

WOUND DRESSING MATERIALS

A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressing comprising the materials, methods of treatment with the materials, and methods of making the materials.

TREATMENT OF BIOFILMS

The present invention relates to a peptide or peptidomimetic for use in the treatment of a biofilm-associated infection in a subject, wherein said peptide or peptidomimetic a) carries a net positive charge,- b) is 1 to 6 amino acids in length or is an equivalently sized peptidomimetic; and c) is amphipathic in nature, having one or more lipophilic groups, one of said lipophilic groups comprising at least 7 non-hydrogen atoms.

HEMOSTATIC SPONGE

The present invention provides a hemostatic porous sponge comprising a matrix of a fibrous biomaterial and particles of a fluid absorbing, particulate material adhered to said matrix material, a method of producing these sponges and their use for wound healing.

FIBRIN SEALANT COMPOSITIONS AND METHODS FOR UTILIZING SAME

The subject invention relates to fibrin sealants. More specifically, the subject invention relates to the use of a fibrin sealant wherein a composition comprising fibrin monomer or a composition comprising noncrosslinked fibrin is utilized as a component of the fibrin sealant.

NUCLEIC ACID ENCODING TGF-.BETA. AND ITS USES

Nucleic acid encoding TGF-.beta. has been isolated and cloned into vectors which are replicated in bacteria and expressed in eukaryotic cells. TGF-.beta. is recovered from transformed cultures for use in known therapeutic modalities. Nucleic acid encoding TGF-.beta. is useful in diagnosis and identification of TGF-.beta. clones.

MEDIUM AND MATRIX FOR LONG-TERM PROLIFERATION OF CELLS

A cell culture medium and hydrogel matrix for long term storage and proliferation of cells is provided. The cell culture medium and hydrogel matrix may include an effective amount of polar amino acids, the polar amino acids selected from the group consisting of arginine, lysine, histidine, glutamic acid, and aspartic acid. One embodiment of the cell culture medium comprises about 5 to about 150 mM of polar amino acids. The hydrogel matrix comprises about 3 to about 150 mM of polar amino acids. L-arginine and L- glutamic acid are preferably supplemented in the cell culture medium. L- arginine, L-lysine, and L-glutamic acid are preferably supplemented in the hydrogel matrix. A method of maintaining viability and functioning of a transplant is also provided. The method of maintaining viability of a transplant includes encapsulating the cells in a hydrogel matrix and injecting the encapsulated cells into the host organism. The matrix of the present invention may also be used to promote vascularization ...

ANTITHROMBOGENIC MEMBRANE MIMETIC COMPOSITIONS AND METHODS

The present Specification describes materials and methods which provide for improved performance of medical prostheses, including vascular graft material, artificial heart valves, and other implanted materials. The materials comprising bound thrombomodulin or a functionally equivalent derivative protein, provide for fewer undesirable side effects including inflammation, thromboses and neointimal hyperplasia.

HYDROGEL-CONTAINING MEDICAL ARTICLES AND METHODS OF USING AND MAKING THE SAME

METHOD FOR PREPARING A HAEMOSTATIC COMPOSITION

The present disclosure relates to a method for preparing a haemostatic composition comprising thrombin, the method comprising the step of reconstituting a dry thrombin directly in a paste, such as a paste comprising a biocompatible polymer. The haemostatic composition comprising thrombin may be prepared from a dry thrombin composition and a paste in a single step operation and be used for treatment of a wound.

BETA-SOLENOID PROTEINS AND THEIR APPLICATION IN TEXTILE PRODUCTION

The present invention provides synthetic fibres with advantageous properties such as high tensile strength and which can be produced by recombinant biotechnological means. The invention also provides the constituent components from which the fibres are assembled, along with fabrics formed from the synthetic fibres. Items comprising the fibres and fabrics of the invention are also included.

SEALANT FORMULATION AND USES THEREOF

The present invention relates to a sealant formulation comprising a blend containing fibrinogen and an exogenous activator of a member of a mammalian blood clotting cascade.

PROTEIN MATRIX MATERIALS, DEVICES AND METHODS OF MAKING AND USING THEREOF

The present invention relates to protein matrix materials and devices and the methods of making and using protein matrix materials and devices. More specifically the present invention relates to protein matrix materials and devices that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, encapsulated or coated stent devices, vessels, tubular grafts, vascular grafts, wound healing devices including protein matrix suture material and meshes, skin/bone/tissue grafts, biocompatible electricity conducting matrices, clear protein matrices, protein matrix adhesion prevention barriers, cell scaffolding and other biocompatible protein matrix devices. Furthermore, the present invention relates to protein matrix materials and devices made by forming a film comprising one or more biodegradable protein materials, one or more biocompatible solvents and optionally one or more pharmacologically ...

MATRIX PROTEIN COMPOSITIONS FOR WOUND HEALING

Active enamel substances may be used for the preparation of a pharmaceutical or cosmetic composition for healing of a wound, improving healing of a wound, soft tissue regeneration or repair, or for preventing or treating infection of inflammation ...

ANTIMICROBIAL AND IMMUNOSTIMULATORY SYSTEM COMPRISING AN OXIDOREDUCTASE ENZYME

The present invention relates to an antimicrobial and immunostimulatory s ystem, applications thereof and a process for the production of the antimicr obial and immunostimulatory system. The present invention provides a storage -stable antimicrobial and immunostimulatory system comprising an oxidoreduct ase enzyme, a substrate for the oxidoreductase enzyme and hydrogen peroxide in an aqueous solution wherein the substrate for the oxidoreductase enzyme i s present up to 90% by weight and water is present up to 20% by weight based on the weight of the total composition; the system has a pH from approximat ely 4 to 8; and the system provides a two-stage hydrogen peroxide release. ...

MODIFIED BIOPOLYMERS AND METHODS OF PRODUCING AND USING THE SAME

Modified biopolymers, such as, charge-modified biopolymers, cross-linked biopolymers, and cross-linked, charge-modified biopolymers are provided along with methods of producing and using the same.

COMPOSITIONS AND METHODS FOR IMPROVING SKIN QUALITY

Provided herein are methods for improving skin quality in a subject comprising administering to the skin a pharmaceutical composition comprising a polypeptide covalently bound to a hydrophilic polymer and/or a polysaccharide covalently bound to a hydrophilic polymer.

NON-ADHERENT HYDROGEL COATING FOR WOUND DRESSINGS AND METHODS FOR MAKING THE SAME

A method for preparing a hydrogel coating for a wound dressing to provide the wound dressing with non-adhesion properties without interfering with the bioactivity of the agents contained in the wound dressing. The hydrogel coating is formed by treating the substrate with O2 plasma before applying a hydrogel precursor solution onto the substrate, and then curing the hydrogel precursor onto the substrate to form the hydrogel coating on the surface of the substrate. Hydrogel coatings for a wound dressing and wound dressings having a hydrogel coating are further described.

PHARMACEUTICAL PREPARATION AND METHOD OF ITS PRODUCTION AND USE

Thus, the present invention provides a composition in powder form comprising highly dispersed silica particles, polymethylsiloxane particles, and a cationic surfactant, wherein at least 25 % by weight of the cationic surfactant is present in primary polymethylsiloxane particles carrying the cationic surfactant on their surface and/or in agglomerates of these primary particles.

WOUND PACKING MATERIAL COMPRISING CHEMOEFFECTOR

A wound packing material, particularly suitable for use in negative pressure wound therapy, comprising a porous material admixed with a chemoattractant. This disclosure further provides methods of manufacturing the wound packing material, and therapeutic methods of using the wound packing material.

BIOPOLYMERIC MEMBRANE FOR WOUND PROTECTION AND REPAIR

The present invention relates to a conformable and semi-permeable biopolymeric membrane suitable for tissue repair and protection. This membrane contains a first layer made from randomly oriented, reconstituted biopolymer fibers and, on top of the first layer, a coating layer made from biopolymer fibers.

IMPROVED CROSS-LINKED COMPOSITIONS

Improved compositions comprising a cross-linkable protein or polypeptide, and a non-toxic material which induces cross-linking of the cross-linkable protein. The compositions are optionally and preferably prepared in a non-phosphate buffer solvent. Optionally and preferably, the cross-linkable protein includes gelatin and any gelatin variant or variant protein as described herein. Optionally and preferably, the non-toxic material comprises transglutaminase (TG), which may optionally comprise any type of calcium dependent or independent transglutaminase, which may for example optionally be a microbial transglutaminase (mTG).

METHOD OF FORMING DEXTRAN AND THROMBIN SHEETS

A method of forming hemostatic sheets. Dextran and water are mixed to form a dextran-water mixture. The dextran-water mixture is formed into a first support layer. Fibrinogen and thrombin are mixed to form a fibrinogen and thrombin mixture. The fibrinogen and thrombin mixture is dispersed on the first support layer to form a hemostatic sheet.

USE OF GM-CSF AND G-CSF TO PROMOTE ACCELERATED WOUND HEALING

... 2081104 9214480 PCTABS00015 A method utilizing GM-CSF and G-CSF to promote accelerated wound healing in mammals is described. This method comprises administering topically to the mammal a therapeutically effective amount of either of these two polypeptides. In additon, such methods comprising admixtures containing either G-CSF or GM-CSF and at least one other protein are also disclosed.

HEMOSTATIC COMPOSITION FOR LOCAL HEMOSTASIS

... 2121028 9306855 PCTABS00021 Method for arresting local bleedings by topical use of FVIIa and a hemostatic composition containing FVIIa together with a biologically compatible carrier which permits said FVIIa to remain in contact with said bleeding wound.

SELF-SUPPORTING SHEET-LIKE MATERIAL OF CROSS-LINKED FIBRIN FOR PREVENTING POST OPERATIVE ADHESIONS

The self-supporting sheet-like material of cross-linked fibrin has a regular pore size. It is used as a bio-mechanical barrier for the treatment of internal traumatic lesions, in particular for the prevention of adhesion formation as post-operative complication. In the course of this it can be used either alone or in combination with a fibrin glue acting as a haemostatic agent. Since the material in terms of its composition and general structure is similar to endogenous products, it has, inter alia, an excellent biocompatibility, bio-degradability and bio-resorbability.

PERMEABLE, LIQUID FLOW CONTROL MATERIAL

A permeable, liquid flow control material composed of: 1) a permeable sheet having a plurality of individual exposed surfaces, at least a portion of which have a surface energy of less than about 45 dynes/cm; and 2) amphiphilic proteins adsorbed onto at least some individual exposed surfaces to define a gradient distribution of amphiphilic protein coating along at least one dimension of the permeable sheet so that the adsorbed amphiphilic protein coating provides controlled wettability along at least one dimension of the liquid flow control material. Desirably, the liquid flow control material is substantially free of fugitive amphiphilic proteins. The material may be used as a permeable, bodyside cover material for absorbent personal care products.

CHEMICAL MODIFICATION OF BIOMEDICAL MATERIALS WITH GENIPIN

Biocompatible cross-linked materials, suit- able for use in implants, wound dressings, and blood substitutes, are described. The materials are prepared by cross-linking biological substances, such as collagen, chitosan, or hemoglobin, with genipin, a naturally occurring cross-linking agent. The cross-linking agent has much lower toxic- ity than conventionally used reagents, and the cross-linked products have good thermal and me- chanical stability as well as biocompatibility.

ARTIFICIAL BODILY FLUID

There is provided a bodily fluid simulant made from red blood cells in an amount between about 10 and about 60 weight percent, egg white in an amount between 20 and 50 weight percent, and plasma.

WOUND HEALING COMPOSITIONS

Compositions useful for accelerating wound healing in mammals are based on chemical analogs of angiotensin II or fragments thereof.

Verfahren zur Herstellung einer Wundgelantine

Verfahren zur Herstellung eines schwammähnlichen Produktes.

Eponge destinée à des usages médicaux et procédé de fabrication de celle-ci.

Verfahren zur Herstellung von Trägern für Arzneimittel.

Procedimento per la produzione di materiale spugnoso proteico.

Verfahren zur Behandlung von Flächengebilden aus faserhaltigem Zellulosematerial

Verfahren zur Herstellung chirurgischer Hilfsmittel aus Fibrin

Procédé de préparation d'un corps fibreux

[...][...].

Lactoferrin compositions and methods of wound treatment

The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies.

Wound dressing materials

A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressing comprising the materials, methods of treatment with the materials, and methods of making the materials.

Solid dressing for treating wounded tissue

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue.

Product for the management of inflammations, pressure sores and/or oral sores (aphthas) as well as the use of such product

The invention relates to a product for the management of inflammations, pressure sores and/or oral sores (aphthas) which is made predominantly, and preferably completely, from a bioresorbable material, with the bioresorbable material exhibiting a flexible and/or compressible pad element which adheres to the mucosa, and in particular being designed completely as a pad element.

Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds

According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.

Cross-linked compositions

Improved compositions comprising a cross-linkable protein or polypeptide, and a non-toxic material which induces cross-linking of the cross-linkable protein. The compositions are optionally and preferably prepared in a non-phosphate buffer solvent. Optionally and preferably, the cross-linkable protein includes gelatin and any gelatin variant or variant protein as described herein. Optionally and preferably, the non-toxic material comprises transglutaminase (TG), which may optionally comprise any type of calcium dependent or independent transglutaminase, which may for example optionally be a microbial transglutaminase (mTG).

Hemostatic sponge

The present invention provides a hemostatic porous composite sponge comprising i) a matrix of a biomaterial and ii) one hydrophilic polymeric component comprising reactive groups wherein i) and ii) are associated with each other so that the reactivity of the polymeric component is retained, wherein associated means that—said polymeric component is coated onto a surface of said matrix of a biomaterial, or—said matrix is impregnated with said polymeric material, or—both.

Silk-Based Ionomeric Compositions

Disclosed herein are pH-dependent silk fibroin-based ionomeric compositions and colloids, and methods of making the same. The state of the silk fibroin ionomeric compositions is reversible and can transform from a gel-like colloid to a more fluid-like solution, or vice versa, upon an environmental stimulus, e.g., pH. Thus, the silk-based ionomeric compositions and colloids can be applied in various industries, ranging from electronic applications to biomedical applications, such as sensors, gel diodes, absorbent materials, drug delivery systems, tissue implants and contrast agents.

Collagen pad

The present invention relates to a collagen pad and to processes for the manufacture thereof. One aspect of the invention provides a process for the manufacture of a collagen pad from a plurality of collagen particles, said process comprising steps of forming a dispersion of the collagen particles in an aqueous acid solution; and adding a flocculating agent to the dispersion to form a collagen floe. A further aspect of the invention provides a process for the manufacture of a collagen pad, wherein said process comprises a step of centrifuging the product of a flocculation reaction, said flocculation reaction comprising adding a flocculating agent to a dispersion of collagen particles in an aqueous acid solution to form a collagen floe. The collagen pad may be used, for example, in wound care.

Compositions and methods for platelet enriched fibrin constructs

Compositions and methods are provided for tissue constructs that promote wound healing. The composition comprises a dimensionally stable fibrin construct for local administration to a wound site or region. In one embodiment, the fibrin construct is a wound healing composition, including components that promote wound healing, such as platelets, growth factors, white blood cells and fibrin clots. In another embodiment, the tissue treatment composition includes (i) aggregated fibrin, (ii) blood cells, and (iii) optionally, growth factors and/or other proteins.

REINFORCED ABSORBABLE MULTILAYERED HEMOSTATIC WOUND DRESSING

The present invention is directed to a reinforced absorbable multilayered hemostatic wound dressing comprising a first absorbable nonwoven fabric, a second absorbable woven or knitted fabric, thrombin and/or fibrinogen. 118-. (canceled)19. A method for making a multilayered wound dressing having a first absorbable nonwoven fabric , one or more second absorbable woven or knitted fabric , thrombin and/or fibrinogen , comprising the steps of:(a) crimping absorbable polymer fibers or yarns in the range of about 10 to 30 crimps per inch;(b) cutting the crimped fibers or yarns to a staple length between about 0.1 and 2.5 inch;(c) carding the staple to form the first absorbable nonwoven fabric while controlling the humidity to about 20 to 60%, at a room temperature of about 15 to 24° C.;(d) attaching the first absorbable nonwoven fabric to the second absorbable woven or knitted fabric;(e) applying thrombin and/or fibrinogen to the first absorbable nonwoven fabric.20. The method of claim 19 , wherein the humidity of the environment for step (c) is from about 40 to 60% claim 19 , at a room temperature of about 15 to 24° C.21. The method of claim 19 , where the first absorbable nonwoven fabric comprises fibers comprised of aliphatic polyester polymers or copolymers of one or more monomers selected from the group consisting of lactic acid claim 19 , lactide claim 19 , glycolic acid claim 19 , glycolide claim 19 , ε-caprolactone claim 19 , p-dioxanone claim 19 , and trimethylene carbonate.22. The method of claim 21 , where the first absorbable nonwoven fabric comprises glycolide/lactide copolymer.23. The method of claim 21 , where the second absorbable woven or knitted fabric comprises oxidized polysaccharides.24. The method of claim 23 , where the second absorbable woven or knitted fabric comprises oxidized cellulose.25. The method of claim 24 , where the second absorbable woven or knitted fabric comprises oxidized regenerated cellulose.26. The method of claim 24 , where the ...

METHODS FOR STEPWISE DEPOSITION OF SILK FIBROIN COATINGS

The invention provides a method for the controlled assembly of layered silk fibroin coatings using aqueous silk fibroin material. The methods described herein can be used to coat substrates of any material, shape, or size. Importantly, the described methods enable control of the biomaterial surface chemistry, thickness, morphology and structure using layered thin film coatings, or bulk coatings. Furthermore, the methods can be performed in all water and do not require intensive chemical processing enabling controlled entrapment of labile molecules such as, drugs, cytokines, and even cells or viruses to generate functional coatings that can be used in a variety of applications. 1. A composition comprising a substrate coated with silk fibroin , wherein the silk fibroin coating the substrate comprises a therapeutic agent.2. The composition of claim 1 , wherein the composition is selected from the group consisting of vascular wound repair devices claim 1 , hemostatic dressings claim 1 , patches claim 1 , glues claim 1 , and sutures.3. The composition of claim 1 , wherein the therapeutic agent comprises an agent for enhancing wound healing.4. The composition of claim 1 , wherein the therapeutic agent is selected from the group consisting of antiproliferatives claim 1 , antineoplastics claim 1 , antiinflammatories claim 1 , antiplatelets claim 1 , anticoagulants claim 1 , antifibrins claim 1 , antithrombins claim 1 , antimitotics claim 1 , antibiotics claim 1 , antioxidans claim 1 , and combinations thereof.5. The composition of claim 1 , wherein the composition is formulated for topical administration.6. The composition of claim 1 , wherein the therapeutic agent is present as a liquid or a finely divided solid.7. The composition of claim 1 , wherein the therapeutic is controlled released over a period of about 2 to about 90 days.8. The composition of claim 1 , wherein the therapeutic agent is released in an amount of about 1 ng/day to 1 mg/day.9. The composition of claim ...

Stabilized protease composition

A composition is provided, which comprises a serine protease; a reversible inhibitor of said serine protease; and a stabilizing agent M having the formula I: Also provided are uses of the composition as a medicament, and other uses and methods employing its various properties.

ACTIVATED LEUKOCYTE CONDITIONED SUPERNATANT AND USES FOR WOUND HEALING

Disclosed are therapeutic, activated leukocyte conditioned supernatants, methods of making them, and methods of using the conditioned supernatants to repair or promote healing of wounds. 162-. (canceled)63. A substantially cell-free activated leukocyte-conditioned supernatant (ALCS) , wherein the ALCS is made by(a) obtaining activated leukocytes; contacting the activated leukocytes with an incubation medium to form an incubation composition; incubating the incubation composition at a temperature and time sufficient to increase the concentration of at least one cytokine or growth factor in the incubation composition; and removing leukocytes from the incubation composition to produce a substantially cell-free ALCS activated leukocyte-conditioned supernatant (ALCS), or(b) incubating human leukocytes under conditions of time and temperature to activate the leukocytes; subjecting the leukocytes to hypo-osmotic shock; adding to the leukocytes subjected to the hypo-osmotic shock to a salt solution in an amount which restores isotonicity; separating the leukocytes from the resulting isotonic solution; mixing the separated leukocytes with serum to form an incubation composition; incubating the incubation composition under conditions of time and temperature to increase the concentration of at least one cytokine or growth factor in the incubation composition; and separating the leukocytes and other cellular matter from the incubation composition to produce a substantially cell-free ALCS.64. A substantially cell-free activated leukocyte-conditioned supernatant (ALCS) comprising at least about 1000 pg/mL human IL-8 , at least about 10-20 pg/mL human IL-6 , and at least about 20 pg/mL human TNFalpha.65. The use of the ALCS according to any one of or in the manufacture of a medicament for the treatment of a wound or the inhibition of the onset of infection in a wound; (i) the wound is a decubital ulcer, a pressure ulcer, a lower extremity ulcer, tendonitis, a deep sternal wound, a ...

High strength chitin composite material and method of making

The present invention is directed to a composite laminar material with high mechanical strength and methods of fabricating the material. The invention also provides a method of attaching a medical implant device to tissue.

Antimicrobial and immunostimulatory system comprising an oxidoreductase enzyme

The present invention relates to an antimicrobial and immunostimulatory system, applications thereof and a process for the production of the antimicrobial and immunostimulatory system. The present invention provides a storage-stable antimicrobial and immunostimulatory system comprising an oxidoreductase enzyme, a substrate for the oxidoreductase enzyme and hydrogen peroxide in an aqueous solution wherein the substrate for the oxidoreductase enzyme is present up to 90% by weight and water is present up to 20% by weight based on the weight of the total composition; the system has a pH from approximately 4 to 8; and the system provides a two-stage hydrogen peroxide release.

Continuous Fiber Layer Comprising an Active Substance on the Basis of Bio-polymers, the Use Thereof, and Method for the Production Thereof

The invention relates to continuous fiber layers comprising an active substance on the basis of bio-polymers, comprising a fibrous, bio-polymer active substance carrier, and at least one active substance associated with the carrier and releasable from the continuous fiber layer; to formulations comprising an active substance, the formulations comprising such continuous fiber layers; to the use of continuous fiber layers comprising an active substance for the production of formulations comprising an active substance; and to a method for the production of continuous fiber layers comprising an active substance. The invention further relates to corresponding continuous fiber layers comprising an active substance and to the use thereof for the production of wound treatment and hygiene products, and to the respectively produced wound treatment and hygiene products. 1. An active ingredient-containing fibrous sheetlike structure comprising a fibrous , polymeric , soluble and/or degradable active ingredient carrier and at least one active ingredient which is associated with the carrier and can be released by the fibrous sheetlike structure ,wherein the carrier comprises, as a polymer component, at least one biopolymer which may additionally have been chemically and/or enzymatically modified, andwherein the biopolymer is selected from a C16 spider silk protein comprising the amino acid sequence of SEQ ID NO: 2, an S16 protein comprising the amino acid sequence of SEQ ID NO: 6; or a spinnable protein derived from these proteins having a sequence identity of at least about 60%.2. The fibrous sheetlike structure of claim 1 , wherein the fibrous sheetlike structure is obtained by means of a spinning process.3. The fibrous sheetlike structure of claim 2 , wherein the fibrous sheetlike structure is obtained by means of electrospinning of an electrospinnable solution which comprises at least one biopolymer and at least one active ingredient.4. The fibrous sheetlike structure of ...

FAST-CLOTTING WOUND DRESSINGS

Disclosed herein are fast-clotting wound dressings impregnated with one or more hemostatic agents including, for example, tissue factor, and optionally, one or more phospholipids. Such dressings may be used to initiate blood clotting on a wound of a subject. 1. A fast-clotting wound dressing impregnated with tissue factor and/or analogues , homologues , precursors or derivatives thereof.2. The fast-clotting wound dressing of claim 1 , further comprising one or more phospholipids impregnated within said dressing.3. The fast-clotting wound dressing of wherein said one or more phospholipids are phosphatidylcholine claim 2 , phosphatidylserine and/or sphingomyelin.4. The fast-clotting wound dressing of claim 1 , wherein the tissue factor is human tissue factor.5. The fast-clotting wound dressing of claim 4 , wherein the human tissue factor is produced using recombinant technology.6. The fast-clotting wound dressing of claim 1 , wherein said wound dressing initiates clotting within 120 seconds of application to a wound.7. The fast-clotting wound dressing of claim 1 , wherein said wound dressing initiates clotting within 27 seconds of application to a wound.8. The fast-clotting wound dressing of claim 1 , wherein tissue factor is impregnated at a concentration of 5 pmoles-100 pmoles per bandage.9. The fast-clotting wound dressing of claim 1 , wherein the dressing is further impregnated with a secondary clotting factor.10. The fast-clotting wound dressing of claim 1 , wherein the dressing is further impregnated with one or more secondary agents selected from the group consisting of pharmaceuticals claim 1 , antifungal agents claim 1 , topical pain reducing medication claim 1 , pharmaceuticals claim 1 , anti-inflammatory agents and tissue enzyme inhibitors.11. The fast-clotting wound dressing of claim 10 , wherein the pharmaceutical is an analgesic claim 10 , an anti-inflammatory agent claim 10 , or an antibacterial.12. A fast-clotting wound dressing impregnated with one or ...

SYNTHETIC SURFACTANT-FREE FINISH, SHEET HAVING SYNTHETIC SURFACTANT-FREE FINISH, ARTICLES HAVING SHEET WITH SYNTHETIC SURFACTANT-FREE FINISH, AND RELATED METHODS

Nonwoven (and film) topsheet and acquisition/distribution materials treated with a hydrophilic, synthetic surfactant-free finish, absorbent articles for infant or incontinence care that contain these materials, and methods for apply such finishes and/or making such absorbent articles. 1. A hydrophilic , synthetic sheet comprising:a sheet of synthetic material having a first surface;where the sheet comprises a hydrophilic finish including molecules of a water-soluble proteins dispersed on the first surface;where the finish includes substantially no synthetic surfactants; andwhere a 0.5-15% aqueous solution of the water-soluble protein has a surface tension of less than 49 milliNewtons per meter (mN/m).2. The sheet of claim 1 , wherein the finish does not include synthetic materials capable of reducing the surface tension of water below 50 mN/m.3. The sheet of claim 1 , wherein the sheet comprises a nonwoven fabric or a film.4. The sheet of claim 1 , wherein the sheet is a topsheet of an absorbent article.5. The sheet of claim 1 , wherein the sheet is a distribution-acquisition layer of an absorbent article.6. The sheet of claim 1 , wherein the water-soluble protein comprises a thermally-denatured protein.7. The sheet of claim 1 , wherein a 1.2-10% aqueous solution of the water-soluble protein has a surface tension of less than 49 mN/m.8. The sheet of claim 1 , wherein at least 0.004 grams of the molecules of the water-soluble protein are dispersed on the sheet for each gram of sheet.9. A disposable absorbent article comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a topsheet comprising the sheet of ;'}a backsheet; andan absorbent core disposed between the topsheet and the backsheet.10. A disposable absorbent article comprising:a topsheet;{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a distribution-acquisition layer comprising the sheet of ;'}a backsheet; andan absorbent core disposed between the distribution-acquisition layer and the backsheet.11. A ...

ANTISEPTIC WOUND DRESSING

The antiseptic wound dressing includes at least nanometer chitin, alkaline earth metal alginate, and an antiseptic material. The nanometer chitin is tubular shaped having diameter 10˜50 nm and length 20˜200 nm. The amount of the nanometer chitin is 0.1%˜5% to the alkaline earth metal alginate. The antiseptic wound dressing is manufactured by mixing nanometer chitin and alkaline earth metal alginate, further mixing with antiseptic material, conducting a wet spinning process to produce fibers, and conducting a non-woven cloth process to obtain the antiseptic wound dressing of the present invention. Therefore, the antiseptic wound dressing is capable of reducing the chance of would infection, and providing superior moisture retention and enhanced wet strength. 1. An antiseptic wound dressing manufactured by a process comprising the steps of:providing a first solution where nanometer chitin is dispersed evenly in water and alkaline earth metal alginate powder is mixed in the water;providing a second solution by mixing an antiseptic material in the first solution;conducting a wet spinning process, where the second solution is filled into a grooving tank storing a grooving liquid which includes 5% calcium chloride solution, when the second solution contacts with the calcium chloride solution, the sodium ions in the alkaline metal alginate swap with calcium ions to form solid fibers of calcium alginate, and the fibers are then washed and dried; andconducting a non-woven cloth process comprising opening, combing, needle-bonding, calendering, and obtaining the antiseptic wound dressing of nanometer chitin calcium alginate;wherein the antiseptic would dressing comprises nanometer chitin, alkaline earth metal alginate, and the antiseptic material;the nanometer chitin is tubular shaped having diameter 10˜50 nm and length 20˜200 nm; andthe amount of nanometer chitin is 0.1%˜5% to the alkaline earth metal alginate.2. The antiseptic wound dressing according to claim 1 , wherein ...

Solid dressing for treating wounded tissue and processes for mixing fibrinogen and thrombin while preserving fibrin-forming ability, compositions produced by these processes, and the use thereof

Fibrin Sealant products are used for topical hemostasis and tissue adherence. They are composed of two main reagents, fibrinogen and thrombin. When mixed in solution fibrinogen is converted to fibrin upon the addition of activated thrombin. Therefore typically these two components are stored separately in a lyophilized or liquid state, and mixed, upon or immediately before, application to a patient. While effective, these products require significant preparation that must take place immediately before application, thus delaying treatment and limiting the use of these haemostatic products to the treatment of mild forms of low pressure and low volume bleeding. Attempts to eliminate this delay and expand the usefulness and effectiveness of these products have resulted in products produced by processes that require the separation of these components and their deposition in distinct layers within the product. The processes described herein permit the mixing of fibrinogen and thrombin during product manufacture, without excessive fibrin formation. The resulting ‘pre-mixed’ fibrin sealant material can then be stored in either a frozen or dried state, or suspended in a non-aqueous environment. Activation of the material to form therapeutic fibrin sealant is accomplished by permitting the product to thaw (if frozen) or by the addition of water or other aqueous fluid, including blood, or other bodily fluids, if dried or suspended in a non-aqueous environment. The resulting material can be used to make a product in which a pre-mixed form of activatable fibrin sealant is a desired component.

IONIC LIQUIDS THAT STERILIZE AND PREVENT BIOFILM FORMATION IN SKIN WOUND HEALING DEVICES

Compositions for enhancing wound healing are disclosed herein. Also disclosed are methods of making the compositions and methods of using the compositions for the prevention of biofilm formation and for the inhibition of pathogen growth and proliferation. 1. A wound care composition , comprising:an ionic liquid (IL) and a neutral species, wherein the ionic liquid is present in an amount of about 0.01% w/w to about 99% w/w; anda protein scaffold comprising a protein solution.2. The wound care composition of claim 1 , wherein the IL is choline geranate (CAGE) or choline citronellate.3. The wound care composition of claim 1 , wherein the wound care composition is incorporated with or impregnated into or coated onto a wound dressing claim 1 , a bandage claim 1 , a gauze claim 1 , a patch claim 1 , a pad claim 1 , tape claim 1 , or a wrap.4. The wound care composition of claim 1 , wherein the ionic liquid is present in an amount of about 40% w/w.5. The wound care composition of claim 1 , wherein the protein solution comprises collagen claim 1 , albumin claim 1 , casein claim 1 , fibrin claim 1 , fibroin claim 1 , gelatin claim 1 , keratin claim 1 , elastin claim 1 , tropoelastin claim 1 , or combinations thereof.6. The wound care composition of claim 1 , wherein the protein scaffold is electrospun.7. The wound care composition of claim 1 , wherein the protein solution is present in an amount of about 1% w/v to about 20% w/v.8. The wound care composition of claim 1 , wherein the protein scaffold is present in an amount of about 10% w/v.9. The wound care composition of claim 1 , comprising IL in an amount of about 0.2% w/w and gelatin in an amount of about 10% w/v gelatin.10. The wound care composition of claim 1 , wherein the neutral species comprises farnesol claim 1 , linalool claim 1 , carvacrol claim 1 , geranic acid claim 1 , citronellic acid claim 1 , cinnamaldehyde claim 1 , eugenol claim 1 , or combinations thereof.11. The wound care composition of claim 1 , ...

METHODS AND DRESSINGS FOR SEALING INTERNAL INJURIES

Disclosed are solid and frozen haemostatic materials and dressing's consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings. 1. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue at least one haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to join or approximate said wounded tissue and/or to reduce the flow of fluid from said wounded tissue , wherein said haemostatic material has a plurality of particles , wherein said particles each have the same composition , and wherein the moisture content of said hemostatic material is from 6% to 44%.2. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue at least one haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to join or approximate said wounded tissue and/or to reduce the flow of fluid from said wounded tissue , wherein said haemostatic material has a plurality of particles , wherein said particles each have the same composition , and wherein the moisture content of said hemostatic material is from 1% to 6%.3. A method for treating wounded internal tissue in a mammal comprising applying to svounded internal tissue at least one haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to join or approximate said wounded tissue and/or to reduce the flow of fluid from said wounded tissue , wherein said haemostatic material is cast or formed as a single piece.4. The method of claim 1 , wherein said haemostatic material includes at least one support layer.5. The method of claim 4 , wherein said support layer comprises a backing material.6. The method of claim 4 ...

MODIFIED BIOPOLYMERS AND METHODS OF PRODUCING AND USING THE SAME

Modified biopolymers, such as, charge-modified biopolymers, cross-linked biopolymers, and cross-linked, charge-modified biopolymers are provided along with methods of producing and using the same. 1. A method for producing a cross-linked , charge-modified biopolymer comprising:combining a biopolymer and at least one charge-modifying agent to form a homogenous reaction blend;reacting the biopolymer and the at least one charge-modifying agent in the homogenous reaction blend; andcross-linking the biopolymer in the homogeneous reaction blend to form a cross-linked, charge-modified biopolymer.2. The method of claim 1 , wherein the combining step further comprises combining a plasticizer and optionally a catalyst with the biopolymer and the at least one charge-modifying agent to form the homogenous reaction blend.3. The method of claim 1 , wherein the cross-linking step further comprises reacting the charge-modified biopolymer with at least one cross-linking agent claim 1 , optionally in the presence of an initiator.4. The method of claim 1 , wherein the reacting and cross-linking steps occur simultaneously.5. The method of any one of claim 1 , further comprising foaming the cross-linked claim 1 , charge-modified biopolymer.6. The method of claim 1 , wherein the cross-linked claim 1 , charge-modified biopolymer comprises a plurality of void spaces formed therein having an average diameter of about 0.1 to about 500 microns.7. The method of claim 1 , wherein the biopolymer comprises at least two different biopolymers claim 1 , optionally wherein one of the at least two different biopolymers is a charge-modified biopolymer.8. The method of claim 1 , wherein the cross-linked claim 1 , charge-modified biopolymer has a net positive charge or a net negative charge.9. The method of claim 1 , wherein the cross-linked claim 1 , charge-modified biopolymer is a polyampholyte.10. The method of claim 1 , wherein the combining step comprises melting blending the biopolymer and the at ...

METHODS OF MAKING BIOACTIVE COLLAGEN WOUND CARE DRESSINGS

A method of preparing a crosslinked, collagen-based wound care dressing is provided, comprising: (a) immersing a sample of fibrous and/or non-fibrous collagen in a buffered acidic, aqueous solution comprising an alcohol; (b) contacting the collagen in solution with a catalytic component comprising 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride for a time at least sufficient to effect reaction between amino and carboxyl groups present on the collagen and to yield crosslinked collagen that is resistant to pronase degradation; and (c) drying the crosslinked collagen to yield a porous, crosslinked collagen article wherein the porous, crosslinked collagen article demonstrates a pore size of 10-500 microns. Also provided are bioactive collagen medical scaffolds for hernia repair prosthetics and surgical incision closure members, prepared using the method above. 1. A method of preparing a crosslinked , collagen-based wound care dressing , comprising:(a) immersing a sample of fibrous and/or non-fibrous collagen in a buffered acidic, aqueous solution comprising an alcohol, wherein the immersion of the sample of fibrous and/or non-fibrous collagen is conducted prior to crosslinking of the collagen;(b) subsequent to step a), contacting the collagen in a separate solution with a catalytic component comprising 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDCI) for a time at least sufficient to effect reaction between amino and carboxyl groups present on the collagen and to yield crosslinked collagen, wherein the crosslinked collagen is resistant to pronase degradation when subjected to a pronase degradation test for at least five hours; and(c) drying the crosslinked collagen to yield a porous, crosslinked collagen article wherein the porous, crosslinked collagen article demonstrates a pore size of 10-500 microns.2. The method of claim 1 , wherein the collagen is a mixture of fibrous and non-fibrous collagen.3. The method of claim 1 , wherein the ...

BIORESORBABLE WOUND DRESSING

The present invention is directed to novel non-woven fabrics containing growth and differentiation factor proteins. Said fabrics are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues. Furthermore, the invention provides wound dressings, pads or implants comprising the novel non-woven fabrics. 1. A non-woven fabric comprising:fibres of a fibre raw material comprising bioresorbable and/or biocompatible polymers, the fibres including at least one biologically active substance, which is distributed in the fibres, wherein the biologically active substance is a GDF-5-related protein.2. The non-woven fabric of claim 1 , wherein the biologically active protein is additionally distributed on the fibres.3. The non-woven fabric of claim 1 , wherein the GDF-5-related protein comprises a cystine-knot-domain with an amino acid identity of at least 60% to the 102 aa-cystine-knot-domain of human GDF-5 according to amino acids 400-501 of SEQ ID NO:2.4. The non-woven fabric of claim 3 , wherein the GDF-5-related protein comprises a cystine-knot-domain with an amino acid identity of at least 70% claim 3 , 80% claim 3 , 90% or 95% to the 102 aa cystine-knot-domain of human GDF-5.5. The non-woven fabric of claim 1 , wherein the fibre raw material is selected from the group consisting of natural polymers claim 1 , synthetic polymers claim 1 , and polymers derived from fossile raw materials claim 1 , each of which may be modified or unmodified claim 1 , and combinations thereof.6. The non-woven fabric of claim 5 , wherein the natural polymers are selected from the group consisting of polypeptides such as collagen claim 5 , gelatin claim 5 , fibrin claim 5 , and casein claim 5 , polysaccharides such as dextran claim 5 , cellulose claim 5 , starch claim 5 , chitin claim 5 , chitosan claim 5 , alginate and hyaluronic acid claim 5 , polynucleotides claim 5 , and synthetic polymers such as polylactide (PLA) claim 5 , polyglycolide (PGA) ...

Sealant Dressing with Removable Intermediate Separating Layer

The present invention is directed to medical devices having a first porous substrate layer with at least a surface coating thereon of a first co-reactive component and a second substrate layer with at least a surface coating layer of a second co-reactive component that reacts with the first co-reactive component, and a removable barrier layer positioned between the first substrate layer and second substrate layer and in contact with said first substrate layer and said second substrate layer. 1. A medical device comprising:a. a first porous substrate layer have at least one major facing surface with at least a surface coating thereon of a first co-reactive component;b. a second substrate layer having at least one major facing surface with at least a surface coating layer of a second co-reactive component that reacts with the first co-reactive component; andc. a removable barrier layer positioned between the first substrate layer and second substrate layer and in contact with at least one major facing surface or a surface coating, each, independently of one another, from said first substrate layer and said second substrate layer.2. A medical device according to wherein the first substrate layer is a porous claim 1 , non-woven mesh constructed from one or more synthetic polymers or copolymer claim 1 , cellulosic materials claim 1 , and blends thereof.3. A medical device according to wherein the second substrate layer is a porous claim 2 , non-woven mesh constructed from one or more synthetic polymers or copolymer claim 2 , cellulosic materials claim 2 , and blends thereof.4. A medical device according to claim 1 , wherein the second substrate layer is non-porous film.5. A medical device according to claim 3 , wherein a non-porous film is applied onto a top facing surface of the second substrate layer.6. A medical device according to wherein at least one major surface of the first substrate layer is coated with a nucleophilic group-containing compound as the first co- ...

Recombinant spider silk protein coatings and adhesives for medical devices

Medical devices made with coatings made from recombinant spider silk proteins are disclosed. Methods to make the devices are also disclosed. Methods for adhering objects to one another using recombinant spider silk proteins are also disclosed.

Composite material

According to embodiments, a composite material is disclosed. The composite material has a multi-layered structure, wherein the multi-layered structure is constituted by a hydrophilic biodegradable polymer and a collagen. In particular, the collagen is strip-shaped and has a fiber length from 1.5 mm to 50 mm. There are at least ten stacked layers per 5 μm of thickness in the multi-layered structure.

Gelatin Non-Woven Structures Produced by a Non-Toxic Dry Solvent Spinning Process

The present application discloses an alternative method for the formation of non-woven with fibers in the 1 to 200 μm range. Using an aqueous solution of gelatin (optionally with <30% of low molecular weight alcohol) the fibers are ejected utilizing pressurized air emitted from nozzle and the non-woven formed directly from the emitted thin fibers. 1. A method of producing fibers of gelatin comprising the steps of:(a) ejecting an aqueous solution of gelatin through a nozzle, wherein glucosaminoglycans (GAGs) are dissolved in the solution prior to ejection, wherein the aqueous solution includes less than 25% low molecular weight alcohol; while(b) emitting pressurized air from air jet bores into the gelatin fibers containing GAGs to attenuate or stretch the gelatin fiber containing GAGs; while(c) collecting the gelatin fibers containing GAGs on a collecting device.2. The method according to claim 1 , wherein the viscosity of the aqueous solution of gelatin is between 1000 and 2000 mPas at a processing temperature of 40° C.3. The method according to claim 1 , wherein the nozzle has an orifice between 0.008 inch and 0.050 inch.4. The method according to claim 1 , wherein the aqueous solution comprises less than 10% low molecular alcohol.5. The method according to claim 1 , wherein the aqueous solution comprises less than 1% low molecular alcohol.6. The method according to claim 1 , wherein the low molecular weight alcohol is selected from the group consisting of methanol claim 1 , ethanol claim 1 , 1-propanol claim 1 , 2-propanol claim 1 , and 1-butanol.7. The method according to claim 1 , wherein the collection takes place in parallel to the ejection.8. The method according to claim 1 , further comprising the step of forming non-woven from the gelatin fibers containing GAGs as they are ejected.9. The method according to claim 1 , further comprising the step of allowing the gelatin fibers containing GAGs to gel prior to drying.10. The method according to claim 1 , ...

WOUND SCREEN

A binding screen comprising a gas-porous solid non-water-dispersible carrier, to which has been substantially irreversibly bound a compound having matrix metalloproteinase binding functionality, particularly doxycycline. 1. A matrix metalloproteinase binding screen , comprising a gas-porous solid non-water-dispersible carrier , to which has been substantially irreversibly bound a compound having and retaining matrix metalloproteinase binding functionality.2. A method of preparing the screen according to claim 1 , wherein a compound having matrix metalloproteinase binding functionality is converted into a chemically active derivative having a chemically active site and leaving the matrix metalloproteinase binding functionality substantially unaffected claim 1 , which compound is then brought into contact with the carrier and is substantially irreversibly bound thereto via the chemically active site.3. The method according to claim 2 , wherein the compound having matrix metalloproteinase binding functionality is converted into a chemically active derivative by introducing an amine group.4. The method according to claim 3 , wherein the carrier comprises cotton having β-D-glucopyranose residues claim 3 , which is treated with sodium periodate claim 3 , which oxidises the β-D-glucopyranose residues to give free aldehydes claim 3 , the amine derivative then being mixed with the treated cotton to form a mix claim 3 , so that the aldehydes undergo nucleophilic attack by the free amine to form carbinolamines claim 3 , the mix then subsequently being treated with a reducing agent which both reduces any unreacted free aldehydes claim 3 , thus preventing any unwanted further reactions claim 3 , and also reduces carbinolamines to alkylamines.5. The method according to claim 3 , wherein the amine functionality is further converted by biotinylation to add a biotin claim 3 , and then brought into contact with the carrier claim 3 , which has been modified with an avidin derivative ...

BETA-SOLENOID PROTEINS AND THEIR APPLICATION IN TEXTILE PRODUCTION

The present invention provides synthetic fibres with advantageous properties such as high tensile strength and which can be produced by recombinant biotechnological means. The invention also provides the constituent components from which the fibres are assembled, along with fabrics formed from the synthetic fibres. Items comprising the fibres and fabrics of the invention are also included. 1. A concatemer of beta solenoid domains , wherein the concatemer comprises at least two beta solenoid domains ,wherein the at least two beta solenoid domains are linked by a linker, andwherein each of the at least two beta solenoid domains comprise an amino acid sequence that comprises at least 4 units of a consensus motif.2. The concatemer of wherein the at least two beta solenoid domains are rod-shaped claim 1 ,optionally wherein one of the at least two beta solenoid domains has a longitudinal axis and a transverse axis and the ratio of longitudinal length to transverse length is at least 2:1, optionally at least 3:1, optionally at least 4:1, optionally at least 5:1, optionally at least 6:1, optionally at least 7:1, optionally at least 8:1, optionally at least 9:1, optionally 10:1;optionally wherein both of the at least two beta solenoid domains have a longitudinal axis and a transverse axis and the ratio of longitudinal length to transverse length is at least 2:1, optionally at least 3:1, optionally at least 4:1, optionally at least 5:1, optionally at least 6:1, optionally at least 7:1, optionally at least 8:1, optionally at least 9:1, optionally 10:1;optionally wherein all of the beta solenoid domains have a longitudinal axis and a transverse axis and the ratio of longitudinal length to transverse length is at least 2:1, optionally at least 3:1, optionally at least 4:1, optionally at least 5:1, optionally at least 6:1, optionally at least 7:1, optionally at least 8:1, optionally at least 9:1, optionally 10:1.3. The concatemer of wherein one or both of the at least two beta ...

LEUCINE BETA ROLL DOMAINS AND USES THEREOF

In one aspect, the invention relates to a peptide that forms a calcium-dependent hydrogel using a rationally engineered beta roll peptide. In the absence of calcium, the peptide is intrinsically disordered. Upon addition of calcium, the peptide forms a corkscrew-like structure. In one embodiment, one face of the beta roll is mutated to comprise leucine residues. In some embodiments, a leucine zipper forming helical domain to the engineered beta roll forms hydrogels by physical cross-linking in calcium rich environments. 1Bordetella pertussis. A beta roll domain comprising at least one repeating unit from the wild-type RTX domain of adenylate cyclase from that has been modified to include at least one modification , said modified repeat unit including an amino acid sequence XXXXXXXXXadhering to the following sequence definition:{'sub': '1', 'a) Xis an amino acid selected from the group consisting of glycine, valine and serine;'}{'sub': '2', 'b) Xis an amino acid selected from the group consisting of glycine, serine, aspartic acid and leucine;'}{'sub': '3', 'c) Xis an amino acid selected from the group consisting of alanine, glutamic acid, glutamine, tyrosine and glycine;'}{'sub': '4', 'd) Xis an amino acid selected from the group consisting of glycine and arginine;'}{'sub': '5', 'e) Xis an amino acid selected from the group consisting of aspartic acid, alanine, asparagine, serine, and histidine;'}{'sub': '6', 'f) Xis an amino acid selected from the group consisting of aspartic acid and asparagine; and'}{'sub': 7', '8', '9', '7', '8', '9, 'i': 'Bordetella pertussis.', 'g) wherein at least one of X, X, and Xis mutated to a leucine residue from a non-leucine residue as found in a corresponding X, X, and Xposition of the at least one repeating unit from the wild-type RTX domain of adenylate cyclase from'}2. The beta roll of claim 1 , wherein the beta roll domain further comprises X claim 1 , wherein Xis appended adjacent to X claim 1 , and wherein{'sub': '10', '(a) Xis ...

COMPOSITIONS HAVING ABSORBABLE MATERIALS, METHODS, AND APPLICATORS FOR SEALING INJURIES

Disclosed are solid and frozen haemostatic materials utilizing an absorbable scaffolding material and consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings, particularly for the treatment of injured tissue via endoscopic or minimally-invasive surgical techniques. 1. A haemostatic material cast as a single piece comprising an absorbable scaffolding , a fibrinogen component , a fibrinogen activator , and water , wherein said haemostatic material is made by combining said fibrinogen component , fibrinogen activator and water at 4° C.+/−2° C. , absorbing said fibrinogen component , fibrinogen activator and water into said absorbable scaffolding , freezing said resulting scaffolding , and lyophilizing.2. The haemostatic material of claim 1 , further comprising one or more of the following: at least one binding agent claim 1 , at least one filler; at least one solubilizing agent; at least one foaming agent; and at least one release agent.3. The haemostatic material of claim 1 , further comprising at least one therapeutic supplement selected from the group consisting of antibiotics claim 1 , anticoagulants claim 1 , steroids claim 1 , cardiovascular drugs claim 1 , growth factors claim 1 , antibodies (poly and mono) claim 1 , chemoattractants claim 1 , anesthetics claim 1 , antiproliferatives/antitumor agents claim 1 , antivirals claim 1 , cytokines claim 1 , colony stimulating factors claim 1 , antifungals claim 1 , antiparasitics claim 1 , antiinflammatories claim 1 , antiseptics claim 1 , hormones claim 1 , vitamins claim 1 , glycoproteins claim 1 , fibronectin claim 1 , peptides claim 1 , proteins claim 1 , carbohydrates claim 1 , proteoglycans claim 1 , antiangiogenins claim 1 , antigens claim 1 , nucleotides claim 1 , lipids claim 1 , liposomes claim 1 , fibrinolysis inhibitors claim 1 , procoagulants ...

Absorbent materials

The present invention provides dry-creped absorbent material comprised of gelling fibres intended for use particularly, but not necessarily exclusively, as wound dressings or as a component (absorbent substrate) of a wound dressing, as well as wound dressings comprising the absorbent material.

WOUND CARE TREATMENT AND METHODS OF MAKING AND USING SAME

A method of treating a wound including applying a wound care treatment to the wound, the wound care treatment including a preparation composed of morselized amnion tissue and amniotic fluid cells adsorbed to a porous collagen matrix and optionally, glycosaminoglycan. The morselized amnion tissue includes organized amniotic extracellular matrix (ECM), amniotic tissue cells and growth factors contained within the ECM and amniotic tissue cells. The porous collagen matrix is provided as a solid sheet, a meshed or perforated sheet or a flowable material. 1. A method of treating a wound comprising:providing a first preparation including amnion tissue and amniotic fluid cells, wherein the amnion tissue is morselized amnion tissue and includes organized amniotic extracellular matrix (ECM), amniotic tissue cells and growth factors contained within the ECM and amniotic tissue cells,providing a porous matrix including a mammalian collagen and optionally, glycosaminoglycan (GAG),combining the first preparation with the porous matrix to form a second preparation, the second preparation including a portion of the first preparation adsorbed to the porous matrix, andapplying the second preparation to a mammal.2. The method according to wherein the first preparation is combined with the porous matrix to form the second preparation no more than about ten minutes prior to applying the second preparation to the wound.3. The method according to wherein the ECM includes amnion-derived collagen claim 1 , fibronectin claim 1 , laminin claim 1 , proteoglycans and glycosaminoglycans.4. The method according to wherein the amnion-derived collagen is derived from an epithelium layer claim 3 , a basement membrane layer claim 3 , a compact layer claim 3 , a fibroblast layer claim 3 , an intermediate layer and a spongy layer of the amnion tissue.5. The method according to wherein the mammalian collagen is selected from the group consisting of Type I collagen claim 1 , Type III collagen claim 1 , a ...

ANTIMICROBIAL PEPTIDES AND COMPOSITIONS, METHODS, ARTICLES & KITS RELATING THERETO

Peptides are described herein, in particular peptides having antimicrobial properties, as are compositions, articles, and kits comprising such peptides, and methods for using the peptides. 135-. (canceled)37. The peptide of claim 36 , wherein said peptide has a modification at an N- and/or C-terminus of the peptide.38Klebsiella pnuemoniae's. The peptide of claim 36 , wherein the peptide has a potential to depolorize membrane.39. The peptide of claim 36 , wherein the peptide has an antimicrobial activity.40. The peptide of claim 36 , wherein the one or more substitutions claim 36 , insertions claim 36 , additions claim 36 , or deletions of said peptide is at least 80% homologous to the SEQ ID NO.:1 to the SEQ ID NO.:8.41K pneumoniae. The peptide of claim 36 , wherein MIC activity of the peptide against carbapenem-resistant strain is less than 20 μM.42K pneumoniae. The peptide of claim 41 , wherein the MIC activity of the peptide against carbapenem-resistant strain is less than 10 μM.43. A composition comprising the peptide of the .44. The composition of claim 42 , further comprises an excipient.45. A polynucleotide encoding the peptide of the .46. A method comprising: administering to a subject the peptide of or a polynucleotide encoding said peptide and treating an infection by a microbial organism in the subject.47. The method of claim 46 , wherein a route of administration of the peptide or a polynucleotide encoding said peptide is a topical claim 46 , an oral claim 46 , a parenteral claim 46 , a rectal claim 46 , a dermal claim 46 , a transdermal claim 46 , an intrathoracic claim 46 , an intrapulmonary claim 46 , or an intranasal route.48. The peptide of claim 36 , wherein the peptide reduces biofilm.49. A method comprising: contacting a sample with the peptide of under a condition such that the LPS binds to the peptide to form a complex; detecting the complex and determining lipopolysaccharide (LPS) in a sample.50. The method of claim 49 , wherein the sample is ...

NOVEL POLYPEPTIDES AND MEDICAL USES THEREOF

The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant of derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition. 1. A polypeptide comprising or consisting of an amino acid sequence derived from collagen type VI , or a fragment , variant , fusion or derivative thereof , or a fusion of said fragment , variant of derivative thereof ,wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms.2. A polypeptide according to wherein the microorganisms are selected from the group consisting of bacteria claim 1 , mycoplasmas claim 1 , yeasts claim 1 , fungi and viruses.3. A polypeptide according to any one of the preceding claims wherein the polypeptide is capable of binding to the membrane of the microorganism.4. A polypeptide according to any one of the preceding claims wherein the polypeptide is capable of causing membrane disruption of the microorganisms.5. A polypeptide according to any one of the preceding claims which is capable of promoting wound closure.6. A polypeptide according to any one of the preceding claims claim 1 , wherein the polypeptide is capable of exhibiting an antimicrobial effect greater than or equal to that of LL-37.7. A polypeptide according to any one of ...

Cross-Linked Poly-E-Lysine Non-Particulate Support

The invention provides a non-particulate cross-linked poly-ε-lysine polymer. The poly-ε-lysine and cross linker are linked by amide bonds and may the cross linker has at least two functional groups capable of reacting with an alpha carbon amine of poly-ε-lysine. The polymer is suitably insoluble in water and other solvents and is provided in macro form for example a sheet, article or fibre. The macro form polymer is useful in a wide range of applications including wound treatment, as a medical diagnostic comprising a particulate support and a functional material bound or retained by the support and solid phase synthesis of peptides, oligonucleotides, oligosaccharides, immobilisation of species, cell culturing and in chromatographic separation.

NEW WOUND DRESSING COMPOSITIONS

A wound dressing composition comprising a non-viable cell lysate or releasate derived from a hepatocyte cell or an inflammatory cell such as a macrophage. Also provided are wound dressings comprising such compositions, methods of making such compositions, and the use of such compositions for the treatment of wounds. 1. A wound dressing composition comprising a non-viable cell lysate or releasate derived from an inflammatory cell.2. A wound dressing composition according to claim 1 , wherein the cell lysate or releasate is dispersed in or on a pharmaceutically acceptable vehicle.3. A wound dressing composition according to claim 2 , wherein said pharmaceutically acceptable vehicle is in the form of a solid sheet claim 2 , a semi-solid ointment claim 2 , an apertured solid sheet claim 2 , a web claim 2 , a woven fabric claim 2 , a knitted fabric claim 2 , a nonwoven fabric claim 2 , a hydrophilic foam claim 2 , a freeze-dried sponge or a solvent-dried sponge.4. A wound dressing composition according to claim 3 , wherein said pharmaceutically acceptable vehicle comprises a bioabsorbable freeze-dried sponge.5. A wound dressing composition according to claim 1 , wherein the cell releasate or lysate is dispersed in or on a solid vehicle that comprises claim 1 , or consists essentially of claim 1 , a solid bioabsorbable material selected from the group consisting of collagen claim 1 , chitosan claim 1 , oxidized cellulose claim 1 , or mixtures thereof.6. A wound dressing composition according to which is substantially dry.7. A wound dressing composition according to claim 1 , wherein the composition further comprises from about 0.01 to about 10% by weight on a dry weight basis of one or more wound healing therapeutic substances.8. A wound dressing composition according to which is substantially sterile.9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. A process for the production of a wound dressing comprising the steps of lysing hepatocyte or ...

ANTIMICROBIAL BIOPOLYMER COMPOSITIONS, METHODS OF SYNTHESIS, AND APPLICATIONS OF USE

Biopolymer compositions comprising antimicrobial peptides (AMPs) for treating infections such as bacterial infections, viral infections, fungal infections, and parasitic infections. The compositions herein may also be used for treating infections associated with antibiotic-resistant bacteria, antifungal-resistant fungi, antiviral-resistant viruses, or for treating biological warfare agents (BWAs) such as and . The present invention also provides methods of synthesis of said biopolymer compositions, wherein AMP biopolymers can be synthesized as an artificially engineered protein by genetically fusing an AMP; a protein that behaves similarly to polymer tethers; and a protein as a modifiable material platform that can transform to self-assembled nanoparticles, self-standing films, or adhesives to easily attach tethered AMPs onto any biomaterial surface for various clinical applications. 1. An antimicrobial biopolymer composition comprising ,a) an elastin-like polypeptide (ELP), wherein the ELP comprises one or more pentapeptide repeats consecutively linked, wherein at least one of the pentapeptide repeats comprises a tyrosine residue;b) an antimicrobial peptide (AMP); and ["wherein the peptide tether connects to the AMP at the AMP's N-terminus, C-terminus, or both;", 'wherein the ELP is more hydrophobic than the peptide tether., 'c) a hydrophilic peptide tether connecting the ELP and the AMP;'}2. The composition of claim 1 , wherein the one or more pentapeptide repeats is selected from a group consisting of: SEQ ID NO: 3 claim 1 , SEQ ID NO: 4 claim 1 , SEQ ID NO: 5 claim 1 , SEQ ID NO: 6 claim 1 , SEQ ID NO: 7 claim 1 , SEQ ID NO: 8 claim 1 , SEQ ID NO: 9 claim 1 , SEQ ID NO: 10 claim 1 , SEQ ID NO: 11 claim 1 , SEQ ID NO: 12 claim 1 , SEQ ID NO: 13 claim 1 , SEQ ID NO: 14 claim 1 , SEQ ID NO: 15 claim 1 , SEQ ID NO: 16 claim 1 , SEQ ID NO: 17 claim 1 , SEQ ID NO: 18 claim 1 , SEQ ID NO: 19 claim 1 , SEQ ID NO: 20 claim 1 , SEQ ID NO: 21 claim 1 , SEQ ID NO: 22 claim ...

HEMOSTATIC SPONGE

The present invention provides a hemostatic porous composite sponge comprising: 1. A method of manufacturing a hemostatic composite , comprising:contacting a sponge comprising a matrix of a biomaterial in dried form with a reactive polymeric material in the form of a solution so that the biomaterial is impregnated with the reactive polymeric material or the reactive polymeric material is coated onto a surface of the matrix of the biomaterial, or both; anddrying the contacted biomaterial and reactive polymeric material.2. A hemostatic composite comprising a sponge comprising a matrix of a biomaterial that is impregnated with a reactive polymeric material obtained by the method of .3. A hemostatic composite comprising a sponge comprising a matrix of a biomaterial that is coated with a reactive polymeric material obtained by the method of .4. The method of claim 1 , wherein the reactive polymeric material is a reactive hydrophilic polymeric material.5. The method of claim 1 , wherein the reactive polymeric material is a single reactive hydrophilic polymeric material.6. The method of claim 1 , wherein the reactive polymeric material is a single hydrophilic polymeric material comprising electrophilic reactive groups claim 1 , wherein the hydrophilic polymeric material is a hydrophilic crosslinker.7. The method of claim 1 , wherein the reactive polymeric material comprises a polyethylene glycol (PEG).8. The method of claim 1 , wherein the reactive polymeric material comprises a polyethylene glycol (PEG) comprising two or more reactive groups selected from the group consisting of succinimidyl esters (—CON(COCH)) claim 1 , aldehydes (—CHO) claim 1 , and isocyanates (—N═C═O).9. The method of claim 1 , wherein the biomaterial is impregnated with the reactive polymeric material.10. The method of claim 1 , wherein the reactive polymeric material is coated onto a surface of the matrix of the biomaterial. This application is a divisional of U.S. patent application Ser. No. 14/184 ...

COATING OF FIBERS WITH DIPEPTIDE NANOSTRUCTURES USING ULTRASONIC CAVITATION

Provided herein are composite structures that include a core fiber and a plurality of peptide-based self-assembled nanostructures attached thereto, wherein the nanostructures may be loaded with a bioactive agent, such that the composite structures may act as slow-release drug-delivery medical device. Also provided is process for producing the composite structures, and uses thereof. 1. A composite structure comprising a core fiber and a plurality of peptide-based self-assembled nanostructures (SAPBNSs) attached thereto.2. The composite structure of claim 1 , wherein said SAPBNSs comprise at least one peptide having 2-6 amino-acid residues.3. The composite structure of claim 1 , wherein said peptide comprises at least one aromatic amino acid residue.4. The composite structure of claim 3 , wherein said peptide is a dipeptide.5. The composite structure of claim 4 , wherein said dipeptide is a homodipeptide.6. The composite structure of claim 4 , wherein said homodipeptide is selected form the group consisting of phenylalanine-phenylalanine dipeptide (diphenylalanine peptide; FF) claim 4 , naphthylalanine-naphthylalanine dipeptide claim 4 , phenanthrenylalanine-phenanthrenylalanine dipeptide claim 4 , anthracenylalanine-anthracenylalanine dipeptide claim 4 , [1 claim 4 ,10]phenanthrolinylalanine-[1 claim 4 ,10]phenanthrolinylalanine dipeptide claim 4 , [2 claim 4 ,2′]bipyridinylalanine-[2 claim 4 ,2′]bipyridinylalanine dipeptide claim 4 , (pentahalo-phenylalanine)-(pentahalo-phenylalanine) dipeptide claim 4 , (amino-phenylalanine)-(amino-phenylalanine) dipeptide claim 4 , (dialkylamino-phenylalanine)-(dialkylamino-phenylalanine) dipeptide claim 4 , (halophenylalanine)-(halophenylalanine) dipeptide claim 4 , (alkoxy-phenylalanine)-(alkoxy-phenylalanine) dipeptide claim 4 , (trihalomethyl-phenylalanine)-(trihalomethyl-phenylalanine) dipeptide claim 4 , (4-phenyl-phenylalanine)-(4-phenyl-phenylalanine) dipeptide and (nitro-phenylalanine)-(nitro-phenylalanine) dipeptide.7. ...

PROTEASE MODULATING WOUND INTERFACE LAYER FOR USE WITH NEGATIVE PRESSURE WOUND THERAPY

Systems, methods, and apparatuses for modulating proteases including matrix metalloproteinase (MMP), elastase, and bacterial protease in a negative pressure therapy system are described. A mesh having a sacrificial substrate is included. The sacrificial substrate includes a plurality of collagen fibers reinforced with a supporting material and intersecting with each other to form a network of collagen fibers having a plurality openings. The openings of the plurality of openings have an average area between about 0.5 mmand about 20 mmto permit the flow of negative pressure through the mesh. The sacrificial substrate can also include oxidized regenerated cellulose. 1. A mesh for modulating proteases in a negative pressure therapy system , comprising:a sacrificial substrate including a plurality of collagen fibers reinforced with a supporting material and intersecting with each other to form a network of collagen fibers having a plurality openings; and{'sup': 2', '2, 'wherein the openings of the plurality of openings have an average area between about 0.2 mmand about 20 mmto permit the flow of negative pressure through the mesh.'}2. The mesh of claim 1 , wherein the openings are generally circular in shape and have an average diameter between about 0.5 mm and about 5.0 mm.3. The mesh of claim 1 , wherein the openings are generally circular in shape and have an average diameter between about 1 mm and about 2.5 mm.4. The mesh of claim 1 , wherein the collagen fibers have a diameter of less than about 1 millimeter.5. The mesh of claim 1 , wherein the collagen fibers have a diameter of between about 1 micron and 50 microns.6. The mesh of claim 1 , wherein the network has a thickness between about 5 microns and about 2 millimeters.7. The mesh of claim 1 , wherein the network has a thickness of about 25 microns.8. The mesh of claim 1 , wherein the collagen fibers have a collagen content between about 10% and about 50% of the total material of the collagen fiber.9. The mesh ...

Dressing Augmentation To Promote Epithelialization

A treatment system for applying negative-pressure therapy to a wound site is disclosed. The treatment system may include a non-adherent material for applying to the perimeter of the wound site. In some embodiments, the treatment system may include a tape, a tissue interface, a sealing member, and a negative-pressure subsystem. The tape material may provide a smooth surface along the perimeter of the wound site for protecting the wound edges from stresses and for promoting epithelialization.

MULTIFUNCTIONAL FORMULATION COMPRISED OF NATURAL INGREDIENTS AND METHOD OF PREPARATION/MANUFACTURING THEREOF

This invention relates to a pharmaceutical preparation for the treatment of compromised tissue such as skin wounds and ulcers in humans and animals and a method of preparation. This is a multifunctional natural matrix meant for the treatment of compromised tissues which also relates to the anti-cancer transdermal patch for melanoma therapy. Further, the invention comprises for the treatment of Alzheimer's, and multiple sclerosis also. The composition consists of water-solubilized nano-sized formulation of non-aqueous solvent extract of phytopharmaceuticals in herbal, animal or synthetic biocompatible gel or on matrix coated or both. The composition is used as a topical device for the treatment of compromised tissues in its preferred embodiment. 135-. (canceled)36. A flexible , biocompatible bandage dressing comprising:a biocompatible, porous matrix; and{'i': Emblica officinalis,', 'Camellia sinsensis, 'a dried, phytopharmaceutical formulation on the biocompatible, porous matrix, wherein said dried, phytopharmaceutical formulation has a thickness of between about 10 μm to 500 μm and comprises 0.5 to 20 percent of non-aqueous extract from the plant 1.0 to 20 percent of non-aqueous extract from the plant , and 0.1 to 12 percent of water soluble curcumin.'}37. The flexible claim 36 , biocompatible bandage dressing of claim 36 , wherein said dried claim 36 , phytopharmaceutical formulation comprises 0.2 to 12.0 percent of aloe vera gel.38. The flexible claim 37 , biocompatible bandage dressing of claim 37 , wherein said aloe vera gel comprises 0.5 to 9.0 percent tocopherol.39. The flexible claim 37 , biocompatible bandage dressing of claim 37 , wherein said aloe vera gel is derived from a 0.5 to 3.0 percent aloe vera solution and 1.0 to 10.0 percent nano-silver solution.40. The flexible claim 36 , biocompatible bandage dressing of claim 36 , comprising liposomes that encapsulate at least a portion of said phytopharmaceutical formulation claim 36 , said liposomes having a ...

Fibrinogen composition, method and wound articles

Provided is a method of forming a fibrinogen hydrogel composition, the method including providing a fibrinogen hydrogel or precursor thereof, comprising fibrinogen hydrogel forming salt. The fibrinogen hydrogel forming salt concentration is greater than or equal to the threshold concentration to form a fibrinogen hydrogel. The method further includes denaturing the fibrinogen hydrogel such as by heating. The method optionally further includes combining the fibrinogen hydrogel with a carrier material. When present, the concentration of the carrier material typically ranges from 0.1 to about 50 wt.-%. The method further includes reducing the salt concentration below the threshold concentration to form a fibrinogen hydrogel.

Polymer-Collagen Composite Film And Method Of Forming The Same

The present invention provides a polymer-collagen composite film and a method of forming the same. In the method, a surface of a polymer substrate is treated by plasma, and collagen is then grafted to the surface, thereby forming the polymer-collagen composite film. The composite film has good hydrophilicity and biocompatibility.

Partially-denatured protein hydrogels

Provided herein are partially-denatured protein (e.g., albumin) hydrogels and methods of manufacture (e.g., pH induction) and use (e.g., drug delivery) thereof.

Bio-based superabsorbents prepared via the macromonomer approach

A novel bio-based superabsorbent polymer material based on a proteinaceous natural polymer is introduced herein. There is further disclosed a method for the manufacture of such a bio-based crosslinked superabsorbent polymer material. The method includes, but not limited to, introducing polymerizable unsaturated groups onto the natural polymer or its derivative so as to yield a macromonomer. The macromonomer can be formed by covalently binding unsaturated carbon-carbon double bonds to a proteinaceous substrate through a reaction of a selected chemical compound and the amino group on the proteinaceous substrate. The macromonomer is then copolymerized with unsaturated co-monomer(s) to form a crosslinked superabsorbent material.

Sealant Dressing with Protected Reactive Components

The present invention is directed to multi-layered wound dressings having a carrier layer, at least two sublayers, wherein each sublayer contains at least one reactive, cross-linkable component and the at least two reactive, cross-linkable components are co-reactive with the other and at least one reactive, cross-linkable has a protective leaving group and a buffering salt agent.

IMPROVEMENTS IN AND RELATING TO COLLAGEN BASED MATERIALS

There are provided collagen based polymeric materials comprising collagen molecules and/or collagen derived molecules which have been functionalised by the addition of one or more ethylenically unsaturated moieties and which have been cross-linked via said moieties. Also provided are collagen based compositions and methods of producing collagen based polymeric materials. 1. A collagen based polymeric material comprising collagen molecules and/or collagen derived molecules which have been functionalised by the addition of one or more ethylenically unsaturated moieties and which have been cross-linked via said moieties.2. A collagen based polymeric material according to claim 1 , wherein the ethylenically unsaturated moiety is glycidyl methacrylate (GMA) claim 1 , 4-vinylbenzene chloride (4VBC) claim 1 , or methacrylic anhydride (MA).3. A collagen based polymeric material according to or claim 1 , wherein the material comprises collagen molecules which have been functionalised by the addition of one or more ethylenically unsaturated moieties and which have been cross-linked via said moieties.4. A method of producing a collagen based polymeric material wherein the method comprises cross linking functionalised collagen and/or collagen derived molecules having one or more ethylenically unsaturated moieties.5. A method according to claim 4 , wherein the method comprises the steps of:(a) Functionalising collagen and/or collagen derived molecules by the addition of one or more ethylenically unsaturated moieties; and(b) Cross linking of the functionalised collagen and/or collagen derived molecules of (a).6. A method according to claim 4 , wherein the method comprises the steps of:(a) Functionalising collagen by the addition of one or more moieties comprising a vinyl group; and(b) Crosslinking of the functionalised collagen and/or collagen derived molecules of (a).7. A collagen based composition comprising a functionalised collagen and/or collagen derived molecule claim 4 , ...

Systemic and Topical Application of Platelet Microparticles to Treat Bleeding in Trauma Patients

The present disclosure is directed to blood dotting compositions comprising platelet microparticles, method of using said compositions, and methods of preparing the same. 1. A blood clotting composition comprising:isolated platelet microparticles; one or more factors selected from fibrinogen (Factor I), von Willebrand factor, Factor II, Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, Factor XII, Protein C (PC), Protein S (PS), antithrombin III (ATIII); and a pharmaceutical carrier;wherein fibrinogen is at about 10-1000 mg/deciliter (dL), Factor V is at about 0.5-2.0 International Unit (IU), Factor VII is at about 0.5-4.0 IU, Factor VIII is at about 0.2-2.0 IU, Factor IX is at about 0.5-3.0 IU, Factor XI is about 0.5-3.0 IU, Factor XII is at about 1.0-7.0 IU, Protein C (PC) is at about 25-300% activity, Protein S (PS) is at about 10-150% activity, antithrombin III (ATIII) is about 25-250% activity.2. The composition of claim 1 , wherein the composition has either prothrombin time that is within a normal reference range or an activated partial thromboplastin time that is within a normal reference range.3. (canceled)4. The composition of claim 1 , wherein the composition has a blood clot initiation time (R-time) of less than three minutes when measured using thromboelastography.5. The composition of claim 1 , wherein the concentration of platelet microparticles in the composition is >10″ microparticles/μl.6. The composition of claim 1 , wherein the composition comprises two or more of the factors or all eight factors.7. (canceled)8. The composition of claim 1 , wherein the composition is formulated for topical administration or systemic administration.9. The composition of claim 8 , wherein the composition is formulated as a spray claim 8 , powder claim 8 , cream claim 8 , gel claim 8 , or ointment.10. (canceled)11. A wound dressing comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the blood clotting composition of and'}a wound dressing ...

Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds

According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.

COMPOSITIONS AND METHODS FOR PLATELET ENRICHED FIBRIN CONSTRUCTS

Compositions and methods are provided for tissue constructs that promote wound healing. The composition comprises a dimensionally stable fibrin construct for local administration to a wound site or region. In one embodiment, the fibrin construct is a wound healing composition, including components that promote wound healing, such as platelets, growth factors, white blood cells and fibrin clots. In another embodiment, the tissue treatment composition includes (i) aggregated fibrin, (ii) blood cells, and (iii) optionally, growth factors and/or other proteins. 120-. (canceled)21. A bioimplantable construct , comprising:a fibrin construct derived from whole blood, having a growth factor enriched surface concentrated with blood cells and platelets capable of releasing a growth factor and a growth factor depleted surface, the fibrin construct being dimensionally stable and suturable.22. The construct of claim 21 , wherein the growth factor depleted surface is substantially lacking in blood cells.23. The construct of claim 21 , wherein the growth factor depleted surface is substantially lacking in red blood cells.24. The construct of claim 21 , wherein the growth factor depleted surface includes white blood cells.25. The construct of claim 21 , wherein the fibrin construct has a resiliency that is defined by an elongation at break strength of at least about 200%.26. The construct of claim 21 , wherein the fibrin construct has a strength that is defined by an ultimate strength of at least about 0.15 MPa.2730. The construct of claim 21 , wherein the fibrin construct has a strength that is defined by a compression strength of at least about kPa28. The construct of claim 21 , wherein the fibrin construct is a folded construct that is folded upon itself so that adjacent halves of the growth factor enriched surface contact each other and form an inner portion of the folded construct while the growth factor depleted surface forms an outer portion of the folded construct.29. The ...

TISSUE PATCH

Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment. For example, in some embodiments, tissue patches are made by applying a compressive force to a liquid medium comprising fibrinogen (and/or fibrin) between two surfaces (e.g., within a syringe or other chamber). A filter can be placed within or near the volume in which the compressive force is applied to the liquid medium such that unwanted material (e.g., water, blood cells, and the like) is passed through the filter while desirable components (e.g., fibrin, fibrinogen, and/or other desirable components) are retained by the filter to form the patch. In this way, the concentration of fibrin (and/or fibrinogen) within the liquid medium can be increased, potentially dramatically, as the compressive force is applied to the liquid-containing composition. In addition, in some embodiments, at least a portion of the fibrinogen and/or fibrin can chemically react (e.g., the fibrinogen can polymerize to form fibrin and/or the fibrin can cross-link) during application of the compressive force. Reaction and concentration can lead to the formation of a highly-concentrated, mechanically robust patch that can be handled relatively easily and provide good structural reinforcement at a wet site, such as a bleeding wound. 1. (canceled)2. A patch , comprising:a primer region comprising a water-activated polymeric adhesive; anda solid matrix positioned over at least a portion of the primer region, the water-activated polymeric adhesive comprises one or more polymers of acrylic acid cross-linked with a polyalkenyl ether and/or a divinyl alcohol; and', 'the patch is configured for application to a tissue surface., 'wherein3. The patch of claim 2 , wherein the solid matrix comprises fibrin.4. The patch of claim 2 , wherein the solid ...

SOLID HEMOSTATIC COMPOSITION AND METHODS OF MAKING SAME

A solid hemostatic composition for use within a biological tissue at an internal treatment site includes a biopolymer configured to cross-link with red blood cells at the site to facilitate clot formation at the site, a first thickener that includes (hydroxypropyl)methyl cellulose (HPMC), a second thickener that includes animal-derived gelatin, and a bioadhesive that includes a low molecular weight poly(lactide). 1. A solid hemostatic composition for use within a biological tissue at an internal treatment site , said solid hemostatic composition comprising:a biopolymer configured to cross-link with red blood cells at the site to facilitate clot formation at the site;a first thickener comprising (hydroxypropyl)methyl cellulose (HPMC);a second thickener comprising animal-derived gelatin; anda bioadhesive comprising a low molecular weight poly(lactide).2. The solid hemostatic composition of claim 1 , wherein said biopolymer comprises a polycationic polymer.3. The solid hemostatic composition of claim 2 , wherein said biopolymer comprises chitosan.4. The solid hemostatic composition of claim 1 , wherein said bioadhesive comprises a biodegradable polymer.5. The solid hemostatic composition of claim 4 , wherein said bioadhesive comprises an acid-terminated poly(D claim 4 ,L-lactide) having a molecular weight ranging from about 1 claim 4 ,000 Dalton to about 5 claim 4 ,000 Dalton.6. The solid hemostatic composition of claim 1 , wherein said animal-derived gelatin is derived from bovine skin.7. The solid hemostatic composition of claim 1 , wherein an amount of said bioadhesive is sufficient to develop a bioadhesional force to tissues surrounding the internal treatment site of at least about 0.15 Newtons.8. The solid hemostatic composition of claim 1 , wherein an amount of said bioadhesive is sufficient to adhere to tissues surrounding the internal treatment site with a peel energy of at least about 0.20 Joules.9. A method of making a solid hemostatic composition for use ...

Keratoprosthesis

The invention comprises a method of making molded, double-crosslinked (i.e., two stages of crosslinking), transparent, collagen materials using a novel combination of diafiltration, lyophilization, and homogenization. The collagen material can be used not only as an ophthalmic device, but also as a tissue scaffold, drug delivery device, wound dressing, or other collagen hydrogel based device.

METHODS OF MAKING BIOACTIVE COLLAGEN WOUND CARE DRESSINGS

A method of preparing a crosslinked, collagen-based wound care dressing is provided, comprising: (a) immersing a sample of fibrous and/or non-fibrous collagen in a buffered acidic, aqueous solution comprising an alcohol; (b) contacting the collagen in solution with a catalytic component comprising 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride for a time at least sufficient to effect reaction between amino and carboxyl groups present on the collagen and to yield crosslinked collagen that is resistant to pronase degradation; and (c) drying the crosslinked collagen to yield a porous, crosslinked collagen article wherein the porous, crosslinked collagen article demonstrates a pore size of 10-500 microns. Also provided are bioactive collagen medical scaffolds for hernia repair prosthetics and surgical incision closure members, prepared using the method above. 1. A method of preparing a crosslinked , collagen-based wound care dressing , comprising:(a) immersing a sample of fibrous and/or non-fibrous collagen in a buffered acidic, aqueous solution comprising an alcohol, wherein the immersion of the sample of fibrous and/or non-fibrous collagen is conducted prior to crosslinking of the collagen;(b) subsequent to step a), contacting the collagen in a separate solution with a catalytic component comprising 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDCI) for a time at least sufficient to effect reaction between amino and carboxyl groups present on the collagen and to yield crosslinked collagen, wherein the crosslinked collagen is resistant to pronase degradation when subjected to a pronase degradation test for at least five hours; and(c) drying the crosslinked collagen to yield a porous, crosslinked collagen article wherein the porous, crosslinked collagen article demonstrates a pore size of 10-500 microns.2. The method of claim 1 , wherein the collagen is a mixture of fibrous and non-fibrous collagen.3. The method of claim 1 , wherein the ...

IMPLANTABLE MESHES FOR CONTROLLING THE MOVEMENT OF FLUIDS

Meshes for use to control the movement of bodily fluids, such as blood, are described herein. The mesh can be partially or completely biodegradable or non-biodegradable. In one embodiment, the mesh is formed from one or more self-assembling peptides. The peptides can be in the form of fibers, such as nanofibers. The peptides can be assembled prior to formation of the mesh or after the mesh has been formed but before it is applied. Alternatively, the mesh can be prepared from unassembled peptides, which assemble at the time of application. The peptides can assemble upon contact with bodily fluids (e.g., blood) or can be contacted with an ionic solution to initiate assembly. 1. An electro-spun mesh for controlling the movement of bodily fluids comprising self-assembling peptides , or peptidomimetics , or combinations thereof ,wherein the mesh comprises electro spun fibers of the self-assembling peptides, or peptidomimetics, andwherein the mesh forms a macroscopic structure that inhibits or prevents passage of bodily fluid through the structure upon contact with physiological fluids at an exposed surgical incision site or an exposed wound site of an animal.2. The mesh of claim 1 , wherein the self-assembling peptides comprise a sequence of amino acid residues conforming to one or more of Formulas I-IV:{'br': None, 'sup': neu', '+', 'neu', '−, 'sub': x', 'y', 'n, '((Xaa−Xaa)(Xaa−Xaa))\u2003\u2003(I);'}{'br': None, 'sup': neu', '−', 'neu', '+, 'sub': x', 'y', 'n, '((Xaa−Xaa)(Xaa−Xaa))\u2003\u2003(II);'}{'br': None, 'sup': +', 'neu', '−', 'neu, 'sub': x', 'y', 'n, '((Xaa−Xaa)(Xaa−Xaa))\u2003\u2003(III);'}{'br': None, 'sup': −', 'neu', '+', 'neu, 'sub': x', 'y', 'n, '((Xaa−Xaa)(Xaa−Xaa))\u2003\u2003(IV);'}{'sup': neu', '+', '−, 'wherein Xaarepresents an amino acid residue having a neutral charge under physiological conditions; Xaa represents an amino acid residue having a positive charge under physiological conditions; Xaa represents an amino acid residue having a negative ...

Haemostatic wound dressing

Haemostatic wound dressings are described. The dressings comprise a non-colloidal porous dressing material, and a plurality of fibrinogen-binding peptides immobilised to the non-colloidal porous dressing material, wherein each fibrinogen-binding peptide comprises: an amino acid sequence Gly-Pro-Arg-Xaa (SEQ ID NO: 1) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Val, preferably Pro, Sar, or Leu; or an amino acid sequence Gly-His-Arg-Xaa (SEQ ID NO: 2) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Pro. The dressings are able to accelerate haemostasis without requiring enzymatic activity. In particular, the dressings to do not rely on the action of exogenous thrombin, and can be stored long-term at room temperature in solution. Methods of making the dressings, and use of the dressings to control bleeding are also described.

MODIFIED BIOPOLYMERS AND METHODS OF PRODUCING AND USING THE SAM

Modified biopolymers, such as, charge-modified biopolymers, cross-linked biopolymers, and cross-linked, charged modified biopolymers are provided along with methods of producing and using the same. 1. A method for producing a cross-linked , charge-modified biopolymer comprising:combining a biopolymer and a plasticizer to form a homogenous reaction blend, wherein the homogenous reaction blend comprises a plasticized biopolymer;reacting the plasticized biopolymer and at least one charge-modifying agent in the homogenous reaction blend to form a charge-modified biopolymer; andcross-linking the charge-modified biopolymer to form a cross-linked, charge-modified biopolymer,wherein the cross-linked, charge modified starch is free of crystalline domains.2. The method of claim 1 , wherein the combining step further comprises combining a catalyst with the biopolymer and the plasticizer to form the homogenous reaction blend.3. The method of claim 1 , wherein the cross-linking step further comprises reacting the charge-modified biopolymer with at least one cross-linking agent.4. The method of claim 1 , wherein the biopolymer comprises at least two different biopolymers.5. The method of claim 1 , wherein the cross-linked claim 1 , charge-modified biopolymer has a net positive charge.6. The method of claim 1 , wherein the combining step comprises melt blending the biopolymer and the plasticizer using a reactive extrusion process.7. The method of claim 1 , wherein the method is carried out in an extruder.8. The method of claim 1 , wherein the cross-linked claim 1 , charge-modified biopolymer is in the form of a particle have a diameter in a range of about 10 microns to about 1000 microns.9. The method of claim 1 , wherein the reacting and/or cross-linking step(s) is/are carried out at a temperature in a range of about 80° C. to about 150° C.10. The method of claim 1 , further comprising heating the cross-linked claim 1 , charge-modified biopolymer at a temperature in a range of ...

DRESSING FOR COMPROMISED WOUND HEALING

The invention relates to a bioactive medical product, or dressing, characterised in that it comprises at least an inner layer formed by a hydrogel and an outer layer formed by a biodegradable and bioabsorbable polyurethane, said inner layer being impregnated with an N-terminal peptide of 20 amino acids of pro-adrenomedullin and the outer layer being impregnated with nanoparticles of bemiparin encapsulated in a biodegradable copolymer or polymer. The active components can be dosed in a sequential and controlled manner with this composition. The invention also relates to a method for producing the two-layer dressing and to the use thereof in medicine, said dressing being specially designed to treat and promote the healing of wounds, such as compromised wounds and ulcers, particularly in patients with diabetes and reduced blood supply. 2. The dressing according to claim 1 , wherein the crosslinking agent is selected from the group consisting of genipin claim 1 , sodium tripolyphosphate claim 1 , sodium glycerol phosphate and salicin.3. The dressing according to claim 2 , wherein the crosslinking agent is genipin.4. The dressing according to claim 1 , wherein the crosslinking agent is contained in the hydrogel in a concentration comprised between 0.5% and 10% by weight with respect to the polymer mixture claim 1 , including both limits.5. The dressing according to claim 1 , wherein the hydrogel consists of 60% by weight of gelatin and 40% by weight of sodium hyaluronate over the polymeric mass of the hydrogel.6. The dressing according to claim 1 , wherein the hydrogel additionally comprises at least one polymer selected from collagen claim 1 , chitosan and dextran.7. The dressing according to claim 1 , wherein the polyurethane has a molecular weight comprised between 3000 and 40000 Daltons claim 1 , including both limits.8. The dressing according to claim 7 , wherein the polyurethane consists of a soft segment ABformed from polycaprolactone diol and pluronic 61 claim 7 ...

COLLAGEN-CONTAINING WOUND DRESSING AND METHOD FOR THE PRODUCTION THEREOF

The invention relates to a method for producing an implant, which is in particular in the form of a wound dressing. The implant consists of a sheet-like structure made of magnesium, which is embedded in a collagen non-woven fabric. 115-. (canceled)16. A method for producing a geometrically stable bioresorbable wound dressing membrane , the method comprising:covering a sheet-like structure made of magnesium or a magnesium alloy with a collagen-containing preparation; anddrying of the collagen-containing preparation.17. The method for producing the wound dressing membrane of claim 16 , wherein the collagen-containing preparation comprises a collagen-containing suspension.18. The method for producing the wound dressing membrane of claim 17 , wherein the suspension includes a native collagen.19. The method for producing the wound dressing membrane of claim 16 , wherein the sheet-like structure comprises a mesh.20. The method for producing the wound dressing membrane of claim 16 , further comprising applying the sheet-like structure onto a support.21. The method for producing the wound dressing membrane of claim 20 , wherein the support comprises a collagen membrane.22. The method for producing the wound dressing membrane of claim 16 , further comprising adjusting the collagen-containing preparation to a pH value of greater than 5.5 claim 16 , at least prior to the covering the sheet-like structure with the collagen-containing preparation.23. The method for producing the wound dressing membrane of claim 16 , wherein the drying of the collagen-containing preparation is performed by lyophilization.24. The method for producing the implant of claim 21 , wherein the support comprises a lyophilized skin of animal or a human origin collagen.25. A wound dressing comprising:a collagen-containing sheet-like structure; anda sheet-like structure made of magnesium or a magnesium alloy, comprising openings, the sheet-like structure made of the magnesium or the magnesium alloy embedded ...

Tissue repair material derived from fish skin and manufacturing method thereof

A tissue repair material derived from fish skin and manufacturing method thereof is applied to provide the tissue repair material suitable for use as a patch, a cover, a carrier, a scaffold, an implant or a reagent in various tissues. The tissue repair material has collagens to improve the wounded tissue repair, and has particular characters for desired tissue repair application. Furthermore, so far the factors of the terrestrial animal transmitted disease (caused by virus) do not survive on the tissue repair material derived from fish skin.

Gel-Within-Gel Wound Dressing

Wound dressings, methods for forming the wound dressings, and methods for using the wound dressings are described. Wound dressings include a crosslinked hydrogel matrix and a plurality of porous absorbent microspheres encapsulated in the crosslinked matrix. The hydrogel matrix and the microspheres can include the same or different hydrogel polymers, e.g., alginates or the like. The wound dressings can be used in treating chronic wounds and burn wounds and can promote autolytic debridement.

Ex Vivo and In Vivo Systems for Evaluating Hemostatic Patches, Sealants, Adhesives on Solid Organs

The present is directed to systems for ex vivo testing performance of a hemostatic or sealing product attached to an animal organ and fully covering a cored channel in said organ, comprising: a pressure sensor positioned proximate to said hemostatic or sealing product in said cored channel; a monitoring or recording device configured to receive pressure readings from said pressure sensor; and a pressurized fluid source connected to said cored channel and configured to supply said pressurized fluid into said cored channel under constant or variable pressure. The present invention is also directed to methods of use for such systems. 1. A system for ex vivo testing performance of a hemostatic or sealing product attached to an animal organ and fully covering a cored channel in said organ , comprising:a) a pressure sensor positioned proximate to said hemostatic or sealing product in said cored channel;b) a monitoring or recording device configured to receive pressure readings from said pressure sensor; andc) a pressurized fluid source connected to said cored channel and configured to supply said pressurized fluid into said cored channel under constant or variable pressure.2. The system of claim 1 , wherein said pressure sensor and said monitoring or recording device are wireless.3. The system of claim 1 , wherein said pressure sensor and said monitoring or recording device are connected by an electric cable.4. The system of claim 1 , wherein said pressure sensor is positioned within 30 mm of said hemostatic or sealing product.5. The system of claim 1 , wherein said pressurized fluid source comprises a perfusion system that is a peristaltic pump or gravity fed system.6. The system of claim 1 , wherein said pressurized fluid is blood and wherein said organ comprises liver claim 1 , spleen claim 1 , or kidney.7. The system of claim 1 , further comprising a vacuum fixation table comprising:a) a body having a flat, contoured, or conformable upper surface andb) a vacuum ...

COMPOSITION OR MATRIX FOR STORAGE OF BACTERIOPHAGES COMPRISING NANOFIBRILLAR CELLULOSE

A composition or matrix comprising a bacteriophage and nanofibrillar cellulose or a derivative thereof in a wet or dry state is disclosed. 1. A composition or matrix comprising a bacteriophage and nanofibrillar cellulose or a derivative thereof in a wet or dry state.2. The composition or matrix according to claim 1 , wherein the composition or matrix is in a wet state and in the form of a hydrogel or a membrane.3. The composition or matrix according to claim 1 , wherein the composition or matrix is in a dry state.4. The composition or matrix according to claim 1 , wherein the bacteriophage is at least partially present as bacteriophage particles in the matrix in a two- or three-dimensional arrangement.5. The composition or matrix according to claim 1 , wherein the nanofibrillar cellulose or a derivative thereof comprises or is native nanofibrillar cellulose.6. An arrangement for storing claim 1 , culturing claim 1 , transporting and/or delivering a bacteriophage claim 1 , the arrangement comprising a solid support and a composition or matrix comprising nanofibrillar cellulose or a derivative thereof in a wet or dry state arranged on the solid support.7. An arrangement comprising a solid support and the composition or matrix according to arranged on the solid support.8. The arrangement according to claim 6 , wherein the solid support is a multiwell plate claim 6 , and the composition or matrix is arranged in one or more wells of the multiwell plate.9. The arrangement according to claim 6 , wherein the arrangement is a medical multi-layer product claim 6 , the solid support is in the form of a layer claim 6 , and the composition or matrix is arranged as a layer on the solid support or impregnated in the solid support.10. A method for storing claim 6 , culturing claim 6 , transporting and/or delivering a bacteriophage claim 6 , wherein the method comprises mixing the bacteriophage with nanofibrillar cellulose or a derivative thereof.11. The method according to claim 10 ...

WOUND DRESSING CONTAINING POLYSACCHARIDE AND COLLAGEN

A wound dressing makes use of a polysaccharide, such as Manuka honey, in combination with collagen in order to suppress the efficacy of matrix metalloproteinases enzymes (“MMPs”) present in chronic wounds. The mixture is applied to an absorbent surface that is designed to absorb the mixed polysaccharide only partially. 1. A dressing for application to a wound comprising:a wound contacting layer for contacting the wound surface, the wound contacting layer comprising:a first polysaccharide; andan MMP suppressing material.2. The dressing of claim 1 , wherein the first polysaccharide is honey.3. The dressing of claim 2 , wherein the MMP suppressing material is collagen.4. The dressing of claim 3 , wherein the collagen is powdered collagen.5. The dressing of claim 2 , wherein the wound contacting layer comprises greater than 90% by weight of honey.6. The dressing of claim 5 , wherein the wound contacting layer comprises less than 10% by weight of collagen.7. The dressing of claim 2 , wherein the wound contact layer comprises between 10% and 45% by weight of honey.8. The dressing of claim 7 , wherein the wound contact layer comprises between 55% and 90% by weight of collagen.9. The dressing of claim 1 , wherein the wound contact layer further comprises a supplemental material.10. The dressing of claim 9 , wherein the wound contact layer comprises less than 50% by weight of honey.11. The dressing of claim 10 , wherein the wound contact layer comprises greater than 50% by weight of the supplemental material.12. A dressing for application to a wound comprising: a first polysaccharide having a first viscosity;', 'a supplemental material; and', 'an MMP suppressing material;, 'a wound contacting layer for contacting the wound surface, the wound contacting layer comprisingwherein the first polysaccharide, the supplemental material and the MMP suppressing material form a mixture in the wound contacting layer having a viscosity that is greater than the viscosity of the first ...

BIOMIMETIC LAMELLAR TISSUE SCAFFOLDS

A biomimetic lamellar tissue scaffold for tissue regeneration comprises a plurality of lamellae formed of a polymer film and each having a first surface and a second surface. A patterned array of polymer nanofibers protrudes from the first surface of each lamella of the plurality. The lamellae form a plurality of interlamellar spaces between the first and second surfaces of adjacent lamellae. Protuberances formed on the first surface of each lamella maintain the interlamellar spaces. The arrays of polymer nanofibers on the first lamellar surface of each lamella protrude into the interlamellar spaces between adjacent lamellae and are configured to influence the propagation and differentiation of cells populated to or recruited to the scaffold. 1. A scaffold for tissue regeneration comprising:a plurality of lamellae formed of a polymer film and each having a first surface with a patterned array of polymer nanofibers protruding from said first surface, and a second surface;a plurality of interlamellar spaces formed between said first surfaces of said lamellae and said second surfaces of adjacent said lamellae; anda plurality of protuberances formed on said lamellae to maintain said interlamellar spaces;wherein said array of polymer nanofibers on said first lamellar surfaces protrude into said interlamellar spaces; andwherein said patterned array is configured to influence the propagation and differentiation of cells populated to or recruited to said scaffold.2. The scaffold of wherein said lamellae further comprise perforations between said first surface and said second surface.3. The scaffold of wherein said polymer film is bioabsorbable.4. The scaffold of wherein said polymer film is treated with another polymer such as poly-L-lysine or poly-D-lysine claim 1 , or a biological substance such as proteoglycans (proteoglycan 4) or glycoproteins to improve surface wetting and cell attachment.5. The scaffold of wherein said lamellae are oriented perpendicular to the plane ...

COMPOSITION FOR USE IN WOUND HEALING IN BURNS

The preset invention relates to a new method for wound healing, particularly in burns, comprising Epinecidin-1 (Epi-1) or Pardaxin (GE33), optionally in the incorporation into collagen. 1. A method for wound healing comprising applying to the wound in a subject in need thereof , a composition comprising Epinecidin-1 (Epi-1) or in the incorporation into collagen , together with a pharmaceutically acceptable carrier.2. The method according to claim 1 , wherein the composition ameliorates excess recruitment of monocytes and macrophage cells claim 1 , and increase VEGF expression claim 1 , and decreased immune responses.3Staphylococcus aureus. The method according to claim 1 , which is effective in preventing or treating infections of Methicillin-resistant (MRSA).4. The method according to claim 1 , wherein Epi-1 is a peptide having an amino acid sequence of SEQ ID NO: 1.5. The method according to claim 1 , for used in wound healing in burns.6. A method for wound healing comprising applying to the wound in a subject in need thereof claim 1 , a composition comprising GE33 or in the incorporation into collagen claim 1 , together with a pharmaceutically acceptable carrier.7. The method according to claim 6 , wherein the composition ameliorates excess recruitment of monocytes and macrophage cells claim 6 , and increase VEGF expression claim 6 , and decreased immune responses.8Staphylococcus aureus. The method according to claim 6 , which is effective in preventing or treating infections of Methicillin-resistant (MRSA).9. The method according to claim 6 , wherein GE33 is a peptide having an amino acid sequence of SEQ ID NO: 2.10. The method according to claim 6 , for used in wound healing in burns.11. A pharmaceutical composition for wound healing in burns claim 6 , comprising Epi-1 or GE33 claim 6 , in the incorporation into collagen claim 6 , together with a pharmaceutically acceptable carrier.12. The pharmaceutical composition according to claim 11 , which is in the form ...

ELECTROSPUN NANOFIBER-BASED DRESSINGS AND METHODS OF MANUFACTURE AND USE THEREOF

Nanofiber structures are provided as well as methods of use thereof and methods of making. 1. A nanofiber structure comprising electrospun nanofibers having a core and shell morphology , wherein said nanofibers comprise an amphiphilic block copolymer , a hydrophobic polymer , and an antimicrobial.2. The nanofiber structure of claim 1 , wherein said antimicrobial is contained within the core of said nanofibers.3. The nanofiber structure of claim 1 , wherein said hydrophobic polymer is contained within the shell of said nanofibers.4. The nanofiber structure of claim 1 , wherein said hydrophobic polymer is polycaprolactone (PCL).5. The nanofiber structure of claim 1 , wherein said nanofiber structure comprises a poloxamer.6. The nanofiber structure of claim 5 , wherein said poloxamer is poloxamer 407.7. The nanofiber structure of claim 1 , wherein said nanofiber structure comprises a plurality of uniaxially-aligned nanofibers claim 1 , random nanofibers claim 1 , and/or entangled nanofibers.8. The nanofiber structure of claim 1 , wherein said antimicrobial is an antibiotic.9. The nanofiber structure of claim 1 , wherein said antimicrobial is a silver containing compound.10. The nanofiber structure of claim 1 , wherein said antimicrobial is an antifungal compound.11. The nanofiber structure of claim 1 , wherein said antimicrobial is an antimicrobial peptide.12. The nanofiber structure of claim 1 , further comprising a coating on said nanofibers.13. The nanofiber structure of claim 1 , wherein said coating comprises an antimicrobial.14. The nanofiber structure of claim 12 , wherein said coating comprises said antimicrobial and said amphiphilic block copolymer.15. The nanofiber structure of claim 1 , further comprising another drug or therapeutic agent.16. The nanofiber structure of claim 15 , wherein said drug or therapeutic agent is selected from the group consisting of a therapeutic agent claim 15 , a growth factor claim 15 , a signaling molecule claim 15 , a cytokine ...

COMPOSITION COMPRISING COLLAGEN AND HONEY

A composition comprising collagen and honey can be produced by addition of an aqueous solution of honey to an aqueous suspension of collagen. The composition is for use in medicine and particularly for use in the treatment of a wound. A method for treatment of a wound comprises administering the composition topically to the skin of a patient. 1. A composition comprising collagen and honey.2. (canceled)3. The composition of claim 1 , wherein the composition is administered to a wound.4. The composition of claim 3 , wherein the wound is inflicted by a burn.5. The composition of claim 1 , wherein:(a) the collagen is bovine collagen; or(b) the honey is of Unique Manuka Factor (UMF)+16; or(c) the collagen is bovine collagen and the honey is of UMF+16.6. (canceled)7. The composition of claim 1 , wherein the composition is in the form of an aqueous suspension.8. (canceled)9. The composition of claim 1 , wherein the composition further comprises water and one or more additional medicaments for the treatment of a wound.10. The composition of claim 1 , wherein the composition further comprises:(a) an aqueous collagen suspension comprising about 0.1% to about 2.0% collagen by weight of the suspension; or(b) a mixture of aqueous honey solution and an aqueous collagen suspension, wherein the mixture comprises about 0.05% to about 5.0% honey by weight; or(c) a combination of (a) and (b).11. (canceled)12. The composition of claim 1 , wherein the composition is in the form of a film or scaffold.13. The composition of claim 12 , wherein the film:(a) has a thickness is in the range of about 5 μm to about 200 μm; or(b) is transparent or translucent; or(c) has a thickness in the range of about 5 μm to about 200 μm and is transparent or translucent.14. (canceled)15. An island dressing comprising a composition claim 12 , wherein the composition comprises collagen and honey surrounded by an additional supporting thin film.16. The island dressing of claim 15 , wherein the additional ...

Activated leukocyte conditioned supernatant and uses for wound healing

Disclosed are therapeutic, activated leukocyte conditioned supernatants, methods of making them, and methods of using the conditioned supernatants to repair or promote healing of wounds.

ADVANCED DIGIT DRESSING

A dressing for treating a wound on a digit includes a digit contact layer configured to substantially prevent adherence of the dressing to the wound and an antimicrobial layer coupled to a wound-facing side of the digit contact layer. The antimicrobial layer includes an antimicrobial substance. A first roll is coupled to a non-wound-facing side of the digit contact layer and unrollable to cover the digit, the digit contact layer, and the antimicrobial layer and a second roll is coupled to the first roll and unrollable to cover the first roll, the digit, the digit contact layer, and the antimicrobial layer.

COMPOSITIONS OF METAL OXIDE SEMICONDUCTOR NANOMATERIALS AND HEMOSTATIC POLYMERS

The present invention provides composition comprising a metal oxide semiconductor nanomaterial coated or dispersed with a hemostatic polymer. 115.-. (canceled)16. A metal oxide semiconductor nanomaterial composition consistinq essentially of a CuO and ZnO nanomaterial and at least one hemostatic polymer wherein the nanomaterial consists of clusters of CuO and ZnO quantum dots consisting of unions of heterojunctions consisting of n-type metal oxide nanoparticles and p-type metal oxide nanoparticles; wherein the hemostatic polymer is adhered or coated on the metal oxide semiconductor nanomaterial; wherein the heterojunctions exhibit an anisotropic conduction of electrons and unequal band gaps; and wherein the nanomaterial exhibits a chemical formula of (CuO)/(ZnO); wherein x is an atomic ratio of the zinc oxide is in the metal oxide semiconductor nanomaterial , and wherein x is about 0.2.17. The metal oxide semiconductor nanomaterial of claim 16 , wherein the metal oxide semiconductor nanomaterial consists of two regions claim 16 , where one region is a surface region and the second region is a core region claim 16 , and the surface region comprises more than 25% by weight of the ZnO and less than 75% by weight of CuO; and the core region comprises less than 10% by weight of the ZnO and more than 90% by weight of the CuO A.18. (canceled)19. The metal oxide semiconductor nanomaterial composition of claim 16 , wherein the hemostatic polymer consists of chitosan claim 16 , alginate claim 16 , gelatin claim 16 , carboxymethyl cellulose claim 16 , polyethylene glycol claim 16 , and combinations thereof.20. The metal oxide semiconductor nanomaterial composition of claim 16 , wherein the hemostatic polymer is from about 1 wt % to about 5 wt % of the metal oxide semiconductor nanomaterial.21. The metal oxide semiconductor nanomaterial composition of claim 16 , wherein the thickness of the hemostatic polymer ranges from about 1.0 nm to about 10.0 nm.22. The metal oxide ...

Hemostatic Agent and Method

One aspect of the invention is a method of treating a wound to clot blood. A sponge material is applied to the wound. The sponge comprises a starch having hemostatic properties and at least one binding agent. The sponge may further comprise a porous, flexible material.

WOUND DRESSINGS

A solid wound dressing material comprising: at least about 5 wt % collagen; from about 6 wt % to about 9 wt % polyvinylpyrrolidone triiodide (PVP-I); and from 0 wt % to about 20 wt % water; wherein the weight percentages are based on the dry weight of the composition. Also provided are methods of making such materials, and wound dressings comprising such materials. In another aspect the invention provides a solid wound dressing material comprising: at least about 5 wt % collagen; from about 10 wt % to about 90 wt % Cadexomer iodine; and from 0 wt % to about 20 wt % water, wherein the weight percentages are based on the dry weight of the composition. Also provided are wound dressings comprising the materials. 1. A solid wound dressing material comprising:at least about 5 wt % collagen;from about 6 wt % to about 9 wt % polyvinylpyrrolidone triiodide (PVP-I); andfrom 0 wt % to about 20 wt % water;wherein the weight percentages are based on the dry weight of the composition.2. A solid wound dressing material according to claim 1 , comprising:from about 7 wt % to about 15 wt. % collagen;from about 6 wt % to about 9 wt % polyvinylpyrrolidone triiodide (PVP-I); andfrom 0 wt % to about 10 wt % water;wherein the weight percentages are based on the dry weight of the composition.3. A solid wound dressing material according to claim 1 , comprising:from about 5 wt % to about 15 wt. % collagen;from about 6.3 wt % to about 8.5 wt % polyvinylpyrrolidone triiodide (PVP-I); andfrom 0 wt % to about 10 wt % water;wherein the weight percentages are based on the dry weight of the composition.4. The wound dressing material according to any preceding claim claim 1 , comprising PVP-I and collagen in a weight ratio of 0.3:1 to 1.5:1 PVP-I:collagen claim 1 , preferably 0.4:1 to 1.2:1 claim 1 , most preferably 0.8:1 to 1.1:16. A solid wound dressing material according to claim 5 , wherein the material comprises from about 7 wt. % to about 25 wt. % collagen claim 5 , for example from about 8 wt ...

WOUND DRESSINGS FOR THE CONTROLLED RELEASE OF THERAPEUTIC

A wound dressing material for controlled activation of a wound healing therapeutic compound in the presence of a protease enzyme in a wound fluid, the material comprising: a medically acceptable polymer; a wound healing therapeutic agent; an inhibitor of the protease enzyme; and a linker group which is cleavable by the protease enzyme, wherein the activities of both the wound healing therapeutic agent and the inhibitor are increased by contacting the wound dressing material with a would fluid containing the protease enzyme. For example, the enzyme may be a matrix metalloproteinase, the therapeutic agent may be a reactive oxygen scavenger, and the inhibitor may be a tissue inhibitor of metalloproteinase (TIMP). 1. A wound dressing material for controlled activation of a wound healing therapeutic compound in the presence of a protease enzyme in a wound fluid , the material comprising:a medically acceptable polymer;a wound healing therapeutic agent;an inhibitor of the protease enzyme; anda linker group which is cleavable by the protease enzyme,wherein the activities of both the wound healing therapeutic agent and the inhibitor are increased by contacting the wound dressing material with a wound fluid containing the protease enzyme.2. A wound dressing material according to claim 1 , wherein the wound healing therapeutic agent and the inhibitor are dispersed in a matrix of the medically acceptable polymer claim 1 , and the polymer comprises the linker group.3. A wound dressing material according to claim 2 , wherein the polymer is cross-linked by the linker group.4. A wound dressing material according to any preceding claim claim 2 , wherein the wound healing therapeutic agent and/or the inhibitor are conjugated to the medically acceptable polymer by the linker group.5. A wound dressing material according to any preceding claim claim 2 , wherein the wound healing therapeutic agent is conjugated to the inhibitor by the linker group.6. A wound dressing material according ...

READY TO USE BIODEGRADABLE AND BIOCOMPATIBLE DEVICE AND A METHOD OF PREPARATION THEREOF

A method is for making a hemostat device. The method includes preparing a homogenous solution of gelatin and chitosan by adding gelatin to water to form a gelatin solution, adding an acid to the gelatin solution to provide an acidified gelatin solution, and adding chitosan to the acidified gelatin solution to form the homogenous solution of gelatin and chitosan. The method also may include air drying the homogenous solution of gelatin and chitosan to provide an air dried scaffold, processing the air dried scaffold to provide a porous sponge, loading the porous sponge with a clotting agent by exposing the porous sponge to the clotting agent in an aqueous solution, and drying the loaded porous sponge. 1. A method for making a hemostat device , the method comprising: adding gelatin to water to form a gelatin solution,', 'adding an acid to the gelatin solution to provide an acidified gelatin solution, and', 'adding chitosan to the acidified gelatin solution to form the homogenous solution of gelatin and chitosan;, 'preparing a homogenous solution of gelatin and chitosan by at least'}air drying the homogenous solution of gelatin and chitosan to provide an air dried scaffold;processing the air dried scaffold to provide a porous sponge;loading the porous sponge with a clotting agent by exposing the porous sponge to the clotting agent in an aqueous solution; anddrying the loaded porous sponge.2. The method of wherein the loading comprises lyophilizing the porous sponge with the aqueous solution.3. The method of wherein the processing comprises cutting and crushing the air dried scaffold.4. The method of wherein the processing comprises stabilizing the air dried scaffold.5. The method of wherein the stabilizing comprises using one of ammonia vapor claim 4 , ammonia solution claim 4 , or alkali solution.6. The method of further comprising washing the porous sponge with water.7. The method of further comprising performing a physico-chemical treatment of the homogenous solution ...

Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds

According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.

Hemostatic products

A hemostatic product that includes a fibrinogen mixture, a thrombin mixture and a biologically tolerable liquid. The fibrinogen mixture includes fibrinogen and at least one fibrinogen stabilizer. The thrombin mixture includes thrombin and at least one thrombin stabilizer. The biologically tolerable liquid is mixed with the fibrinogen mixture and the thrombin mixture to form the hemostatic product.

BIOACTIVE POLYMERIC DRESSING FOR ACCELERATED WOUND CLOSURE

A wound dressing includes: a structural material formed into a dressing; at least one immunomodulatory agent associated with the dressing; and a growth factor associated with the dressing. A wound dressing kit includes: a structural material formed into a wound dressing; an immunomodulatory agent; and a growth factor composition, wherein the structural material contains the immunomodulatory agent and/or the immunomodulatory agent is in a separate composition. A method of treating a wound in a tissue includes: applying an immunomodulatory agent to the wound; applying a wound dressing to the wound; and allowing the wound to heal with the immunomodulatory agent and wound dressing. The application of a growth factor can be before, during and/or after applying the wound dressing to the wound. 1. A wound dressing comprising:a structural material formed into a dressing, wherein the structural material ranges from about 2-25 wt %;at least one immunomodulatory agent associated with the dressing; anda growth factor associated with the dressing.2. The wound dressing of claim 1 , wherein the structural material is biodegradable and/or bioabsorbable.3. The wound dressing of claim 2 , wherein the structural material is a natural substance claim 2 , a synthetic substance claim 2 , or a natural substance that has been chemically modified.4. The wound dressing of claim 1 , wherein the immunomodulatory agent is selected from the group of histamine claim 1 , histamine receptor agonists claim 1 , MCP1 claim 1 , antibodies claim 1 , 2-pyridylethylamine claim 1 , histamine—trifluoromethyl—toluidine dimaleate (HTMT) claim 1 , diphenhydramine claim 1 , terfenadine claim 1 , dimaprit claim 1 , cimetidine claim 1 , ranitidine claim 1 , Nα-methylhistamine claim 1 , azomethine prodrug of (R)-α-methylhistamine claim 1 , impentamine claim 1 , clobenpropit claim 1 , immepip claim 1 , imetit claim 1 , 4-Methylhistamine and combinations thereof.5. The wound dressing of claim 1 , wherein the growth ...

COMBINATION SIS AND VACUUM BANDAGE AND METHOD

A wound care bandage for treating a wound is provided. The bandage includes an SIS layer to be placed on the wound surface and a cover to placed over the wound. The bandage further includes a structure to provide a vacuum space. A method for promoting wound healing is further provided. The method includes applying the above-mentioned wound care bandage to the wound and creating a vacuum in the vacuum space to draw blood controllably from the wound into the SIS layer. 1. A wound care bandage for use with a vacuum source , the wound care bandage comprising:a collagen matrix configured to be placed on a wound of a patient for integration into the wound;a cover configured to be disposed over the wound to provide a sealed environment around the wound; anda support member configured for placement between the collagen matrix and the cover to provide a vacuum space defined by the support member and the collagen matrix and adapted it to receive negative pressure from the vacuum source, the support member having a lower member adapted to be disposed adjacent skin surrounding the wound without sutures or staples, and an upper member coupled to the lower member and configured to be in a spaced-apart relation with the collagen matrix when negative pressure is applied to the vacuum space.2. The bandage of claim 1 , wherein the support member further comprises a middle member coupled between the lower member and the upper member and sufficiently rigid to support the upper member in the spaced-apart relation when negative pressure is applied to the vacuum space.3. The bandage of claim 1 , wherein the middle member includes an inner wall that defines the vacuum space along with the collagen matrix and the upper member.4. The bandage of claim 1 , wherein the support member further comprises a middle member coupled between the lower member and the upper member and wherein the upper member is sufficiently rigid to maintain the spaced-apart relation when negative pressure is applied to ...

ENZYME-DEGRADABLE HYDROGEL FOR DELIVERY OF A PAYLOAD

Various embodiments are described herein for the fabrication enzyme degradable hydrogels useful as payload delivery systems. More particularly, embodiments disclosed herein relate to enzyme-degradable hydrogel systems comprising a crosslinkable polymer, such as a chemically-modified biopolymer, for example, chemically-modified gelatin, the hydrogel formed by a method comprising sequential physical and chemical crosslinking steps, for delivery of various payloads. Enzymes may be selected and administered to tune the release profile of the hydrogel. The payload can be, but not limited to, drugs, markers, cells, or these members encapsulated within another drug delivery such as a nanoparticle, or liposome. The hydrogel system can also be combined with another device such as a contact lens or bandage for wound healing. 1. A hydrogel system for delivering a payload comprising:a hydrogel comprising a crosslinkable polymer, such as a chemically-modified biopolymer, for example, chemically-modified gelatin, the hydrogel formed by a method comprising sequential physical and chemical crosslinking steps; anda payload.2. The hydrogel system of claim 1 , wherein the chemically-modified gelatin comprises methacrylated gelatin claim 1 , acrylated gelatin claim 1 , thiolated gelatin or a combination thereof.3. The hydrogel system of or claim 1 , wherein the chemically-modified gelatin comprises methacrylated gelatin.4. The hydrogel system of any preceding claim claim 1 , wherein the physical crosslinking step comprises incubating a solution comprising the crosslinkable polymer under suitable conditions and for a sufficient period of time to permit physical crosslinking of at least a portion of the crosslinkable polymer.5. The hydrogel system of claim 4 , wherein the solution comprises between about 1%-35% (w/v) of the crosslinkable polymer in a suitable diluent claim 4 , e.g. claim 4 , about 1%-about 5% claim 4 , about 1%-about 10% claim 4 , about 5%-about 30% claim 4 , about 10%- ...

NASAL DRESSINGS AND STENTS

Disclosed are nasal dressings and nasal stents comprising a collagen foam. Also disclosed are methods of making and using such nasal dressings and nasal stents. In an embodiment, a nasal dressing or nasal stent is formed by a method comprising the steps of: forming an aqueous mixture of from 5 to 25 wt % of acid-soluble collagen and from 75 to 95 wt % of collagen fibers, both based on the total solids content of the aqueous mixture, placing the aqueous mixture into a mold, freeze-drying the aqueous mixture while in the mold, thereby forming a collagen foam, and cross-linking the collagen foam. 1. A nasal dressing or nasal stent for treating a wound or inflammation in the nasal cavity of a patient comprising a collagen foam comprising cross-linked acid-soluble collagen and collagen fibers , wherein the nasal dressing or stent comprises the shape of a central hub having a plurality of radiating arms.2. The nasal dressing or nasal stent according to claim 1 , wherein the collagen foam comprises from 5 to 25 wt % of acid-soluble collagen and from 75 to 95 wt % of collagen fibers.3. The nasal dressing or nasal stent according to claim 1 , wherein the collagen foam is formed by lyophilizing an aqueous mixture of from 5 to 25 wt % of acid-soluble collagen and from 75 to 95 wt % of collagen fibers claim 1 , both based on the total solids content of the aqueous mixture claim 1 , followed by cross-linking.4. The nasal dressing or stent according to claim 1 , wherein the nasal dressing or nasal stent is formed by a method comprising the steps of:a. forming an aqueous mixture of from 5 to 25 wt % of acid-soluble collagen and from 75 to 95 wt % of collagen fibers, both based on the total solids content of the aqueous mixture,b. placing the aqueous mixture into a mold,c. freeze-drying the aqueous mixture while in the mold, thereby forming a collagen foam, andd. cross-linking the collagen foam.5. The nasal dressing or stent according to claim 1 , wherein the nasal dressing or ...

MUSSEL ADHESIVE PROTEIN PRODUCT AND USE THEREOF FOR TREATING MUCOSAL INFLAMMATION

The invention relates to a mussel adhesive protein (MAP) and an application thereof in inhibiting catarrh, and specifically, to applications of a MAP or a product thereof in oral mucositis, rhinitis, otitis media, pharyngitis, laryngitis, bronchitis, esophagitis, gastritis, enteritis, cervicitis, endomyometritis, inflammation resulting from inhalation injury, and oral cavity cancer, nasopharyngeal cancer, carcinoma of middle ear, conjunctival cancer, laryngeal cancer, lung cancer, esophageal cancer, stomach cancer, bowel cancer, cervical cancer, endometrial cancer, and other cancers resulting from the inflammation. The MAP can inhibit symptoms such as flush, fever, swell, and pain owing to catarrh, facilitating healing, relieving itch and pain, and having broad applications in the fields of medicines, cosmetics, medical products, disinfection products, healthcare products, foods, and household goods. 112.-. (canceled)13. A method for treating mucosal inflammation , the method comprising:administering to a subject having mucosal inflammation an effective amount of a composition comprising a mussel adhesive protein (“MAP”), wherein said administering treats the mucosal inflammation, and wherein the MAP comprises one or more of the sub-types selected from the group mefp-1, mefp-2, mefp-3, mefp-4, mefp-5, and mefp-6.14. The method according to claim 13 , wherein the MAP comprises mefp-1.15. The method according to claim 13 , wherein the MAP is present in the composition at a concentration of 0.1 to 15.0 mg/mL.16. The method according to claim 13 , wherein the composition is a liquid formulation claim 13 , a gel formulation claim 13 , or a foam formulation.17. The method according to claim 13 , wherein the composition has a pH in the range of 1.0 to 7.0.18. The method according to claim 13 , wherein the composition has a pH in the range of 3.0 to 6.5.19. The method according to claim 13 , wherein the mucosal inflammation is selected from: oral mucositis claim 13 , ...

Combination SIS And Vacuum Bandage And Method

A wound care bandage for treating a wound is provided. The bandage includes an SIS layer to be placed on the wound surface and a cover to be placed over the wound. The bandage further includes a structure to provide a vacuum space. A method for promoting wound healing is further provided. The method includes applying the above-mentioned wound care bandage to the wound and creating a vacuum in the vacuum space to draw blood controllably from the wound into the SIS layer. 1. A wound care bandage for use with a vacuum source , the wound care bandage comprising:a cover having an aperture and configured for placement over a wound to provide a vacuum space around the wound;a collagen-containing layer configured for placement on the wound within the vacuum space;a porous pad configured for placement between the collagen-containing layer and the cover within the vacuum space, the porous pad being removable from the wound and having a plurality of fluid passageways; andan adhesive adapted to couple the cover to skin around the wound to hold the porous pad and the collagen-containing layer in place within the vacuum space.2. The bandage of claim 1 , wherein the collagen-containing layer comprises a submucosa layer.3. The bandage of claim 1 , wherein the collagen-containing layer is selected from the group consisting of submucosa claim 1 , lamina propria claim 1 , and stratum compactum.4. The bandage of claim 1 , wherein the collagen-containing layer is a sheet of a collagen matrix material having a three-dimensional structure.5. The bandage of claim 1 , wherein the collagen-containing layer is configured claim 1 , upon placement into a wound claim 1 , to support tissue remodeling.6. The bandage of claim 1 , wherein the bandage further includes a biological glue configured for placement between the wound and the collagen-containing layer to hold the collagen-containing layer stationary relative to the wound.7. The bandage of claim 6 , wherein the glue is a fibrin sealant.8. ...

Antioxidant Wound Dressing Materials

A wound dressing material comprising a solid bioabsorbable substrate dyed with an antioxidant dyestuff. The substrate may comprise collagen, chitosan or oxidized regenerated cellulose, and the dyestuff may for example be an aniline or acridine dye. The material preferably also comprises a silver salt, whereby the dyestuff stabilizes the silver salt. Also provided are methods of making such materials, and wound dressings comprising such materials. 1. A wound dressing material comprising a solid bioabsorbable substrate dyed with an antioxidant dyestuff.2. A wound dressing material according to claim 1 , wherein the substrate comprises a solid bioabsorbable material selected from the group consisting of collagens claim 1 , oxidized celluloses claim 1 , chitosans claim 1 , galactomannans claim 1 , glycosaminoglycans claim 1 , polylactide /polyglycolide claim 1 , and mixtures thereof.3. A wound dressing material according to claim 2 , wherein the substrate comprises a solid bioabsorbable material selected from the group consisting of collagens claim 2 , oxidized regenerated celluloses claim 2 , chitosans claim 2 , and mixtures thereof.4. A wound dressing material according to claim 3 , wherein the solid bioabsorbable substrate is selected from the group consisting of woven fabrics claim 3 , knitted fabrics claim 3 , nonwoven fabrics claim 3 , freeze -dried sponges claim 3 , solvent -dried sponges and combinations thereof.5. A wound dressing material according to claim 4 , wherein the antioxidant dyestuff is selected from the group consisting of aniline dyes claim 4 , acridine dyes claim 4 , thionine dyes claim 4 , bis- naphthalene dyes claim 4 , thiazine dyes claim 4 , azo dyes claim 4 , anthraquinones claim 4 , and mixtures thereof.6. A wound dressing material according to claim 4 , wherein the antioxidant dyestuff is selected from the group consisting of gentian violet claim 4 , aniline blue claim 4 , methylene blue claim 4 , crystal violet claim 4 , acriflavine claim ...

Multifunctional polymer-nanoparticle composite for first aid and wound care applications

Described herein is a multifunctional polymer-nanoparticle composition for use in wound care applications. Methods of manufacturing the described compositions are also disclosed herein.

COLLOIDAL COLLAGEN BURN WOUND DRESSING PRODUCED FROM JELLYFISH

The present invention relates to methods of forming wound dressings from jellyfish collagen. A jellyfish tissue is provided, after which an acid is added to produce a collagen-salt solution. The solution is mixed to form a viscous colloidal gel, and a film or a film/fabric composite is created from the gel. 121-. (canceled)22. A composition comprising a collagen-salt gel derived from jellyfish , wherein the collagen-salt gel is not solubilized and not cross-linked.23. The composition of claim 22 , wherein the collagen-salt gel is comprised of primarily type II-like collagen.24. The composition of claim 22 , wherein the composition forms a wound dressing.25. The composition of claim 24 , wherein the wound dressing is a film.26. The composition of claim 25 , wherein the film further comprises a fabric.27. The composition of claim 22 , wherein the collagen-salt gel comprises a collagen-salt colloid.28. The composition of claim 27 , wherein the collagen-salt colloid further comprises desalted claim 27 , chopped jellyfish tissue and an acid.29. A wound dressing comprising a collagen-salt gel derived from jellyfish claim 27 , wherein the collagen-salt gel is not solubilized and not cross-linked.30. The wound dressing of claim 29 , wherein the collagen-salt gel comprises primarily type II-like collagen.31. The wound dressing of claim 29 , wherein the composition is a film.32. The wound dressing of claim 31 , wherein the film further comprises a fabric.33. The wound dressing of claim 29 , wherein the wound is a burn.34. The wound dressing of claim 29 , wherein the collagen-salt gel comprises a collagen-salt colloid further comprising desalted claim 29 , chopped jellyfish tissue and an acid.35. A method of treating a wound claim 29 , comprising applying a composition comprising a collagen-salt gel derived from jellyfish to the wound claim 29 , and wherein the collagen-salt gel is not solubilized and not cross-linked.36. The method of claim 35 , wherein the collagen-salt gel ...

METHOD FOR PREPARING ABSORBABLE HAEMOSTATIC COMPOSITION FOR BODY AND HAEMOSTATIC COMPOSITION PREPARED THEREBY

The present disclosure relates to a method for preparing an absorbable haemostatic composition for the body and the haemostatic composition prepared thereby, and the present disclosure is for providing a method for preparing an absorbable haemostatic composition for the body and the haemostatic composition prepared thereby, wherein the haemostatic composition can be used directly on the wound site when bleeding occurs in the surgical area such as surgical operation, trauma, etc. so that hemostasis can be effectively performed, the haemostatic composition can perform wound sealing, tissue repairing promotion, wound surface tissue protection, infection prevention, etc., the haemostatic composition is contained in haemostatic products such as gauze (cotton yarn), sponge, etc. to accelerate the hemostasis speed of the bleeding site and enable rapid hemostasis to be able to shorten the hemostasis time at the same time. 1. A method for preparing an absorbable haemostatic composition for the body , the method comprising:{'b': '10', 'a step (S) of mixing gelatin with sterile distilled water;'}{'b': '30', 'a step (S) of solizing the mixture;'}{'b': '50', 'a step (S) of mixing kaolin with the solized mixture; and'}{'b': '70', 'a step (S) of imparting viscosity to the mixed solution with which kaolin has been mixed,'}wherein when mixing gelatin with sterile distilled water, gelatin is mixed in an amount of 5 to 7 parts by weight with respect to 100 parts by weight of sterile distilled water,wherein when solizing the mixture in which gelatin has been mixed with sterile distilled water, the solization is performed by stirring the mixture to 300 rpm in a temperature range of 70 to 80° C. for 1 hour,wherein when mixing kaolin with the solized mixture, kaolin is mixed in an amount of 4 parts by weight with respect to 100 parts by weight of sterile distilled water, and then the solized mixture with which kaolin has been mixed is stirred and mixed to 350 to 450 rpm in a temperature ...

COMBINATION SIS AND VACUUM BANDAGE AND METHOD

A wound care bandage for treating a wound is provided. The bandage includes an SIS layer to be placed on the wound surface and a cover to be placed over the wound. The bandage further includes a structure to provide a vacuum space. A method for promoting wound healing is further provided. The method includes applying the above-mentioned wound care bandage to the wound and creating a vacuum in the vacuum space to draw blood controllably from the wound into the SIS layer. 1. A wound care bandage for use with a vacuum source , the wound care bandage comprising:a collagen matrix configured to be placed on a wound of a patient for integration into the wound;a semi-rigid dome including an upper member configured for placement over the collagen matrix to provide a vacuum space formed by the upper member and the collagen matrix for receiving negative pressure from the vacuum source;a cover configured to be disposed over the semi-rigid dome and the wound to provide a sealed environment for the vacuum space over the wound; andwherein the semi-rigid dome further includes a lower member adapted to be disposed adjacent skin surrounding the wound before negative pressure is applied to the vacuum space, and wherein the upper member is sufficiently rigid to maintain a spaced-apart relationship with the collagen matrix when negative pressure is applied to the vacuum space.2. The bandage of claim 1 , wherein the upper member includes an inner wall that defines the vacuum space with the collagen matrix.3. The bandage of claim 1 , wherein the collagen matrix comprises a submucosa layer.4. The bandage of claim 1 , wherein the bandage further includes a biological glue for positioning between the wound and the collagen matrix for holding the collagen matrix stationary relative to the wound.5. The bandage of claim 4 , wherein the glue is a fibrin sealant.6. The bandage of claim 1 , wherein the cover includes a first surface and a second surface and the first surface includes an adhesive ...

HIGH HYGROSCOPIC WOUND DRESSING AND PREPARATION METHOD AND USE THEREOF

The present invention discloses a wound dressing and the method of manufacturing. The wound dressing is a knitted fabric including of a fluffy layer of gel-forming fibers and a backing layer of non-gel-forming fibers. The backing layer includes a plain fabric of the non-gel-forming fibers. The gel-forming fibers are knitted onto the backing layer, a middle part of the gel-forming fibers are held in the backing layer, and two ends of the gel-forming fibers project against the backing layer. The length of the middle part of the gel-forming fibers is no more than the length of one loop of the non-gel-forming fibers, and the length of each of the two ends of the gel-forming fibers is between 1-100 mm. 1. An absorbent wound dressing adapted to be applied on wounds and left in place for several days to promote wound healing , the absorbent wound dressing comprising a backing layer of non-gel-forming fibers , and a layer of gel-forming fibers knitted on the backing layer , wherein:the gel-forming fibers are alginate fibers, chemically modified cellulose fibers, chitosan fibers, or a mixture thereof;the non-gel-forming fibers are polyester filaments or yarns, nylon filaments or yarns, PVA filaments or yarns, viscose filaments or yarns, lyocell filaments or yarns, non-gel-forming chitosan filaments or yarns, polyurethane filaments or yarns, polypropylene filaments or yarns, cotton yarns, or a mixture thereof;the backing layer comprises a plain fabric of the non-gel-forming fibers;a middle part of the gel-forming fibers forms loops, and are tied in the backing layer, and two ends of the gel-forming fibers project against the backing layer;a length of the middle part of the gel-forming fibers is no more than a length of one loop of the non-gel-forming fibers, anda length of each of the two ends of the gel-forming fibers is between 1 and 100 mm.2. The absorbent wound dressing of claim 1 , wherein the length of one loop of the non-gel-forming fibers is between 1 and 40 mm.3. The ...

METHOD FOR THE PURIFICATION OF COLLAGEN

A process for the extraction of collagen from collagen-containing matter, wherein the process comprises; incubating the collagen-containing matter in an acidic solution to form an incubant, then diafiltrating the incubant to substantially purify solubilised collagen within the incubant, thereby forming a retentate, then separating the soluble and insoluble matter of the retentate to remove the remaining insoluble matter, wherein the soluble matter is a substantially pure collagen solution. 2. The process according to claim 1 , wherein step (a) is performed at a temperature in the range of about 0° C. to about 22° C.3. The process according to claim 2 , wherein step (a) is performed at a temperature in the range of about 2° C. to about 6° C.4. The process according to claim 1 , wherein step (a) is performed for in the range of about from 1 to 168 h.5. The process according to claim 1 , wherein step (b) is performed using a hollow fibre membrane with a molecular weight cut-off of 50 kDa.6. The process according to claim 1 , wherein step (c) is performed by filtration claim 1 , preferably wherein the filtration is performed by passing the retentate through a filter having a pore selected from the list consisting of 1 μm claim 1 , 20 μm and a combination thereof.7. The process according to claim 1 , further comprising passing the substantially pure collagen solution through one or more filters having a pore size selected from the list consisting of 0.1 μm 0.2 μm claim 1 , 0.3 μm claim 1 , 0.4 μm claim 1 , 0.5 μm 0.6 μm claim 1 , 0.7 μm claim 1 , 0.8 μm and a combination thereof.8. The process according to claim 7 , wherein the substantially pure collagen solution is filtered through a 0.4 μm filter claim 7 , wherein the filtrate obtained therefrom is a mixture of a substantially pure solution comprising monomeric collagen and beta collagen.9. The process according to claim 8 , wherein the substantially pure solution of monomeric collagen and beta collagen is ...

SOLID DRESSING FOR TREATING WOUNDED TISSUE AND PROCESSES FOR MIXING FIBRINOGEN AND THROMBIN WHILE PRESERVING FIBRIN-FORMING ABILITY, COMPOSITIONS PRODUCED BY THESE PROCESSES, AND THE USE THEREOF

Disclosed are solid dressings for treating wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings. 1. A solid dressing for treating wounded tissue in a mammal , said solid dressing comprising at least one haemostatic layer having a wound facing surface and an opposite surface , and consisting essentially of fibrinogen and a solvent consisting of water and a fibrinogen activator , wherein said haemostatic layer is substantially homogenous , and wherein said fibrinogen is present in an amount about 13.0 mg/cmof the wound facing surface of said dressing , and wherein the moisture content of said solid dressing is from 6% to 44%.2. The solid dressing of claim 1 , further comprising at least one support layer.3. The solid dressing of claim 2 , wherein said support layer comprises a backing material.4. The solid dressing of claim 1 , wherein said haemostatic layer also contains a fibrin cross-linker and/or a source of calcium ions.5. The solid dressing of claim 1 , wherein said haemostatic layer also contains one or more of the following: at least one filler claim 1 , at least one solubilizing agent claim 1 , at least one foaming agent and at least one release agent.6. The solid dressing of claim 1 , wherein said haemostatic layer is cast as a single piece.7. The solid dressing of claim 1 , wherein said haemostatic layer is composed of a plurality of particles claim 1 , each of said particles consisting essentially of fibrinogen and thrombin.8. The solid dressing of claim 7 , wherein said haemostatic layer further contains at least one binding agent in an ...

NON-SURGICAL, LOCALIZED DELIVERY OF COMPOSITIONS FOR PLACENTAL GROWTH FACTORS

Described herewith are compositions comprising placental growth factors and methods for non-surgical, localized delivery thereof. The composition is delivered to a diseased or injured organ and/or body part and is formulated in a manner which allows for localized retention of the composition at the site of delivery. 110-. (canceled)11. A composition comprising a sufficient amount of placental growth factors to treat a diseased or injured organ or body part wherein said composition is in the form of a localized mass when applied to or proximate to said diseased or injured organ or body part; wherein said composition is free of modified placental tissue particles; wherein said growth factors are extracted from modified placental tissue; and wherein said modified placental tissue comprises chorion.12. The composition of claim 11 , further comprising a localization agent.13. The composition of claim 12 , wherein the localization agent is a thixotropic agent claim 12 , or a phase changing agent.14. The composition of claim 13 , wherein the thixotropic agent is selected from the group consisting of hyaluronic acid claim 13 , collagen claim 13 , thrombin gels claim 13 , fibrin gels and fibrin glues.15. The composition of claim 13 , wherein the phase changing agent is a gel forming agent.16. The composition of claim 15 , wherein the gel forming agent is a copolymer or tripolymer of oxyethylene and oxypropylene units.17. The composition of claim 12 , wherein the localization agent is selected from the group consisting of a hydrogel claim 12 , a polymer claim 12 , and a collagen gel.18. A method for preparing a composition for localized delivery of placental growth factors claim 12 , comprising combining an aqueous solution of placental growth factors with a sufficient amount of a localization agent claim 12 , whereby the composition is locally retained at the site of delivery upon administration; wherein said composition is free of modified placental tissue particles; ...

Composite Material

Disclosed is a hydrophilic dressing () having appropriate mechanical strength, comprising a composite material () and a film (). The composite material () comprises a hydrophilic substrate material () and a compound () that promotes wound healing, wherein the hydrophilic substrate material () is a reaction product of a hydrophilic polymer, wherein the hydrophilic polymer comprises a hydrophilic monomer, a cross-linking agent and an inorganic silicon-oxygen compound, wherein the compound () that promotes wound healing is distributed in the hydrophilic substrate material (). 1. A composite material which comprises a hydrophilic substrate and a compound that promotes wound healing , wherein the hydrophilic substrate is a reaction product of a hydrophilic polymer , wherein the hydrophilic polymer comprises a hydrophilic monomer , a cross-linking agent , and an inorganic silicon-oxygen compound , wherein the compound that promotes wound healing is distributed in the hydrophilic substrate.2. The composite material of claim 1 , wherein the hydrophilic monomer comprises acrylic acid having a double bond or a derivative thereof claim 1 , acrylamide or a derivative thereof claim 1 , 2-acrylamido-2-methylpropane sulfonic acid or a salt thereof claim 1 , polyethylene glycol or a derivative thereof claim 1 , or a combination thereof3. The composite material of claim 1 , wherein the hydrophilic monomer is from 8 to 80% by weight based on the weight of the hydrophilic polymer.4. The composite material of claim 1 , wherein the crosslinking agent comprises N claim 1 ,N′-methylenebisacrylamide claim 1 , ethylene glycol dimethacrylate claim 1 , polyethylene glycol diacrylate claim 1 , tetraethylene glycol dimethacrylate claim 1 , triethylene glycol dimethacrylate claim 1 , polyethylene glycol dimethacrylate claim 1 , trimethylpropanetrimethacrylate claim 1 , ethylene methacrylate claim 1 , ethylenediamine dimethyl acrylamide claim 1 , glycerol dimethacrylate claim 1 , diethylene ...

ANTIMICROBIAL WOUND DRESSINGS

Wound dressing compositions comprising oxidized regenerated cellulose and poly(hexamyethylene biguanide). The compositions preferably also contain a structural protein, such as collagen. Wound dressings are also provided, comprising an absorbent layer comprising the wound dressing compositions. 1. A wound dressing composition comprising:(a) oxidized regenerated cellulose (ORC); and(b) poly(hexamyethylene biguanide) (PHMB) at a level of from about 0.005% to about 0.02%.2. The wound dressing composition according to claim 1 , comprising a complex of the ORC and the PHMB.3. The wound dressing composition according to claim 1 , wherein the weight ratio of the ORC to the PHMB is from about 200:1 to about 2000:1.4. The wound dressing composition according to claim 1 , further comprising a structural protein.5. The wound dressing composition according to claim 4 , wherein the structural protein is selected from the group consisting of fibronectin claim 4 , fibrin claim 4 , laminin claim 4 , elastin claim 4 , collagen claim 4 , gelatins claim 4 , and mixtures of any two or more thereof.6. The wound dressing composition according to claim 4 , wherein the structural protein comprises collagen.7. The wound dressing composition according to claim 1 , further comprising a polysaccharide gelling agent.8. The wound dressing composition according to claim 7 , wherein the polysaccharide gelling agent is selected from the group consisting of alginates claim 7 , chitosan claim 7 , chitin claim 7 , guar gums claim 7 , pectin claim 7 , starch derivatives claim 7 , cellulose derivatives claim 7 , glycosaminoglycans claim 7 , galactomannans claim 7 , chondroitin salts claim 7 , heparin salts claim 7 , hyaluronic acid and salts thereof claim 7 , and mixtures of any two or more thereof.9. The wound dressing composition according to claim 8 , wherein the polysaccharide gelling agent comprises chitosan.10. The wound dressing composition according to claim 1 , further comprising a gelling ...

HEMOSTATIC SPONGE

The present invention provides a hemostatic porous sponge comprising a matrix of a fibrous biomaterial and particles of a fluid absorbing, particulate material adhered to said matrix material, a method of producing these sponges and their use for wound healing. 1. A hemostatic porous sponge comprising a matrix of a fibrous biomaterial and particles of a fluid absorbing particulate material adhered to said matrix material.2. The sponge according to claim 1 , wherein said fibrous biomaterial comprises collagen.3. The sponge according to claim 1 , wherein said particulate material is a hemostatic material.4. The sponge according to claim 3 , wherein said particulate material is a cross-linked polymer.5. The sponge according to claim 3 , wherein said particulate material comprises gelatin claim 3 , fibrin claim 3 , collagen or any mixture thereof.6. The sponge according to further comprising thrombin or a precursor of thrombin.7. The sponge according to further comprising an adhesive layer.8. The sponge according to claim 7 , wherein said adhesive layer comprises a bioresorbable polymer.9. The sponge according to claim 7 , wherein the adhesive comprises a first cross-linkable component claim 7 , a second cross-linkable component that cross-links with the first cross-linkable component under reaction enabling conditions.10. The sponge according to claim 9 , wherein said first and/or second cross-linkable component comprise PEG or a derivative thereof.11. The sponge according to claim 7 , wherein said adhesive comprises succinimidyl or maleimidyl and thiol or amino groups.12. The sponge according to claim 7 , wherein said adhesive layer is discontinuously coated on at least one side of the sponge.13. The sponge according to being freeze-dried or air-dried.14. The sponge according to comprising a supporting layer with greater tensile strength than the matrix material.15. The sponge according to claim 14 , wherein said supporting layer comprises a bioresorbable polymer.16. ...